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ABSTRACT
Cell-Free Synthesis of Proteins with Unnatural Amino Acids:
Exploring Fitness Landscapes, Engineering Membrane
Proteins, and Expanding the Genetic Code
Song Min Schinn
Department of Chemical Engineering, BYU
Doctor of Philosophy
Unnatural amino acids (uAA) expand the structural and functional possibilities of
proteins. Numerous previous studies have demonstrated uAA as a powerful tool for protein
engineering, but challenges also remain. Three notable such challenges include: (1) the fitness of
uAA-incorporated proteins are difficult to predict and time-consuming to screen with
conventional methods, (2) uAA incorporation in difficult-to-express proteins (e.g. membrane
proteins such as G-protein coupled receptors) remain challenging, and (3) the incorporation of
multiple types of uAA are still limited.
In response, we pose cell-free protein synthesis (CFPS), a rapid and versatile in vitro
expression system, as a platform to explore solutions to these challenges. The “cell-free” nature
of CFPS enables it to accelerate protein expression and tolerate extensive modifications to its
translational environment. In this work, these advantages were utilized to address the
aforementioned challenges by: (1) rapidly expressing and screening uAA-containing proteins, (2)
incorporating uAA in functional G-protein coupled receptor in the presence of membranemimicking lipid additives, and (3) engineer the translational environment extensively towards
multiple uAA incorporation.

Keywords: Synthetic Biology, cell-free protein synthesis, unnatural amino acid, non-natural
amino acid, high throughput screening, linear DNA expression template, membrane proteins, Gprotein coupled receptors, codon reassignment.
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INTRODUCTION

Proteins with Unnatural Amino Acids – Advances and Challenges
Proteins are diverse polypeptide molecules which are ubiquitous and essential to life.
Proteins with useful functions are engineered as therapeutics, nanomaterials and biocatalysts –
thanks to their relatively high specificity, biocompatibility, and biodegradability. Notably,
protein-based biologics have largely driven the recent growth in the biopharmaceutical industry
(Aggarwal 2014; Walsh 2014). However, the majority of these applications have been
constrained by a limited canon of building blocks, called amino acids. Recent advances in
synthetic biology enable proteins to be engineered beyond this constraint with unnatural amino
acids (uAA), whose diverse, non-canonical functions include click-chemistry reactivity (Bundy
and Swartz 2010a), post-translational modification mimicry (Neumann et al. 2008; Wilkins et al.
2014), unique spectroscopic signatures (Cellitti et al. 2008), light- or UV-sensitivity (Neumann
2012), and modification of enzymatic activity (Ravikumar et al. 2015). Proteins with uAA
incorporation (uAA-proteins) are increasingly used to develop biotherapeutics and biocatalysts
(Banerjee et al. 2012; Carter 2011; Pelegri-O’Day et al. 2014; Tan et al. 2014; Wangler et al.
2010; Yu et al. 2015). The present work has sought to further widen the impact of these tools by
exploring them in a versatile in vitro system. Table 1-1 overviews examples of uAA and their
utilities.
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Table 1-1: Unnatural Amino Acids and Their Applications
Unnatural Amino Acid

Phosphothreonine

Useful
Character

Example Application
The uAA was used to site-specifically
encode phosphorylation of threonine
residues which regulate diverse processes
in eukaryotic cells including protein kinase
activation (Zhang et al. 2017).

Posttranslational
modification
mimicry

The uAA was used to produce a
homogeneous population of acetylated
histones to analyze the impact of the
modifications on chromatin array
compaction (Wilkins et al. 2015).

Acetyllysine

p-propargyloxyphenylalanine

p-azidophenylalanine

The uAA was used to immobilize a model
biocatalyst on a surface for stabilization
and recovery, all the while maintaining
Bioconjugation uniform control over enzyme orientation
via Huisgen
(Wu et al. 2015).
1,3-dipolar
cycloaddition
“click”
The uAA was used to create a conjugate
reaction
drug against prostrate cancer by
bioconjugating a suicide enzyme with a
biomarker-specific targeting agent (Martin
et al. 2014).
The uAA was incorporated into a G-protein
coupled receptor and monitored for its
vibrational signatures in the infrared
spectrum, yielding insights into key
conformational changes during receptor
activation (Ye et al. 2010).

Unique
infrared
signature

A flexible and popular method of uAA incorporation is to repurpose a stop codon for
encoding an uAA by suppressing its translation termination function. This suppression is realized
by a heterologous, engineered pair of tRNA and aminoacyl-tRNA synthetase that incorporate the
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uAA at the stop codon while avoiding cross-talk with native translational machineries. Using this
technique, uAA can be site-specifically incorporated at a desired location by mutating the
corresponding codon to a stop codon in the DNA sequence. This method has been flexibly used
with numerous types of uAA in a wide variety of applications, and has been described by several
articulate reviews (Des Soye et al. 2015; Quast et al. 2015; Wang et al. 2006). Despite the
success and versatility of the stop codon suppression method, challenges remain. The presented
work seeks to address three such notable challenges.
(1) Fitness landscape of uAA-proteins is time-consuming to characterize: The location of
uAA within the protein can affect its functional activity and full-length expression yield.
These effects remain poorly understood and difficult to predict. Practical applications
necessitate that such location-dependent effects of uAA be optimized for ideal product
expression and activity.
(2) Incorporation of uAA in difficult-to-express proteins remains challenging:
Successful uAA incorporation into membrane-bound or cytotoxic proteins have been
limited. The former includes G-protein-coupled receptors, a major class of drug targets,
which are difficult to produce due to its high hydrophobicity and stringent folding
requirements.
(3) Incorporation is largely limited to a single type of uAA: The current stop codon
suppression method is largely dependent on the amber stop codon. Other stop codons and
sense codons are less viable for reprogramming due to increased competition from
release factors or native tRNA. Competition from native tRNA are particularly
cumbersome to overcome, as they result in full-length mis-incorporated products rather
than truncated products.
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An alternative method to incorporate uAA into proteins is to globally replace a natural
residue type with uAA throughout the protein (Bacher and Ellington 2007; Singh-Blom et al.
2013). This method does not require heterologous tRNA-synthetase pairs, but fails to deliver
uAA as a unique, site-specific moiety. Another method, solid phase peptide synthesis, explores
the incorporation of uAA entirely outside of evolutionary constraints of the genomic code and
ribosomal translation. However, this method is limited to the synthesis of peptides rather than
full-length proteins, which severely narrows its scope of application. Due to these limitations, the
presented work will focus on the stop codon repression method which provides site-specific
control over uAA incorporation in proteins of varying size and complexities.

Cell-Free Protein Synthesis
The central hypothesis of this work is that these challenges can be effectively addressed
by a versatile, lysate-based in vitro expression system called cell-free protein synthesis (CFPS).
CFPS is assembled from clarified Escherichia coli cell lysate, DNA, energy-generating agents
and various supporting small molecules. CFPS enables rapid and highly customizable expression
environment thanks to the absence of the cell membrane and cellular metabolic processes. We
hypothesize that these advantages can be leveraged to address major challenges in engineering
proteins with uAA, as mentioned above.
CFPS has been used to express a wide variety of protein-based products, including
antibodies (Stech and Kubick 2015; Yin et al. 2012), biocatalysts (Wu et al. 2015),
microarrays (He et al. 2008b; Kilb et al. 2014), virus-like particles (Bundy and Swartz
2011; Smith et al. 2012), cytotoxic oncotherapeutics (Salehi et al. 2015), growth factors
(Goerke and Swartz 2008), and fusion proteins (Kanter et al. 2007). CFPS has been
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adapted to work in batch, continuous exchange, and flow configurations. Lastly, CFPS
permits facile storage and portability via lyophilization (Salehi et al. 2015; Smith et al.
2014a). Several articulate reviews on CFPS can be found elsewhere (Bernhard and
Tozawa 2013; Carlson et al. 2012; Catherine et al. 2013; Henrich et al. 2015; Lee and
Kim 2013; Murray and Baliga 2013; Ranji et al. 2013; Shin and Noireaux 2012; Smith et
al. 2014c; Stech and Kubick 2015; Swartz 2012).
We hypothesize that these advantages could be exploited to address the aforementioned
challenges. Specifically:
(1) Protein expression is accelerated: CFPS can accelerate protein production by being
formatted into low-volume, parallel formats (Okano et al. 2013), bypassing cell culturing
steps of in vivo production, and employing PCR products as linear DNA templates
(Schinn et al. 2016). These features could be exploited to rapidly screen multiple
candidate uAA locations for their fitness in yield and activity.
(2) Production of difficult-to-express proteins is facilitated: Thanks to its cell-free nature,
CFPS can tolerate cytotoxic or water-insoluble elements. In addition, the lack of a cell
membrane allows for direct addition and optimization of supplemental components for
optimal expression. For example, in a recent study, a cytotoxic ribonuclease therapeutic
was successfully expressed in CFPS by continuous addition of purified tRNA (Salehi et
al. 2016). Similarly, functional G-protein coupled receptors have been expressed in CFPS
by addition of membrane-mimicking lipid molecules (Henrich et al. 2015).
(3) Expression environment can be extensively modified: The versatility of CFPS goes
beyond addition of components, allowing for manipulations that would devastate in vivo
systems. CFPS could sustain the wholesale removal and replacements of translational
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components, or alterations of fundamental features of translation, e.g. tRNA-codonamino acid relationships (Cui et al. 2015; Iwane et al. 2016). Such changes could provide
reprogrammable codons beyond the amber stop codon for uAA incorporation.
The presented works utilize CFPS systems derived from Escherichia coli lysate for its
affordability, rapid expression and ease of characterization. E. coli cell lines are wellcharacterized and established, facilitating their applications in CFPS. While many studies have
utilized on the E. coli CFPS system, other reports have productively explored eukaryotic cellfree systems, which better accommodate certain types of complex protein expression, assembly,
and post-translational modifications not found in prokaryotes. The wheat-germ system, in
particular, is a popular eukaryotic CFPS platform that is commercially available, highly
productive, and relatively robust. Despite its time-consuming extract preparation process, it has
been widely used for vaccine development (Arumugam et al. 2014), structural genomics,
proteomics and other studies (Harbers 2014; Lappano and Maggiolini 2011). The yeast system
enjoys a relatively low cost and high stability. These and other CFPS systems – such as rabbit
reticulocyte, insect cells and human systems – remain potentially fruitful frontiers for LET-based
expression.
Another relevant alternative CFPS system is the PURE system, which is constructed from
individually purified components essential for protein synthesis (Shimizu et al. 2005). This
means that the PURE system has reduced concentrations of residual nucleases, making it an ideal
platform for LET-based CFPS. Recently, this advantage was recently demonstrated by the
production of functional membrane proteins SecYEG translocon and F0F1-ATP synthetase in
PURE CFPS using LETs and supplemental liposomes (Kuruma and Ueda 2015).
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Summary and Outline
Unnatural amino acids can expand the rich and productive application space of proteins
with novel structural and functional possibilities. While numerous studies have demonstrated
uAA as a powerful tool for protein engineering, challenges remain. This work focuses
particularly on three of these challenges, and hypothesizes CFPS, a versatile in vitro expression
system, as the basis of their solutions. This hypothesis is explored throughout Chapters 2, 4, 6,
and 8 via adaptations of published research articles which I have co-authored as lead author
(Schinn et al. 2016; Schinn et al. 2017) or significant contributor (Salehi et al. 2017)(Table 1-2).
Table 1-2: The Work’s Central Hypothesis and Organization
Challenge

CFPS as a Solution

Chapter

Publication

Characterizing fitness
landscapes of uAA-proteins

Accelerated screening via rapid,
parallel protein expression

Chapter 2
Chapter 4

(Schinn et al.
2016; Schinn et
al. 2017)

uAA Incorporation in
difficult-to-express proteins

Production of difficult-to-express
proteins is facilitated

Chapter 6

(In preparation)

Incorporation of multiple
types of uAA

Extensive modification of
expression environment for
additional reprogrammable codons

Chapter 8

(Salehi et al.
2017)

In addition, discussions in Chapters 2, 4, 6, and 8 are augmented by supplementary
Chapters 3, 5, 7 and 9, respectively. Chapter 10 provides a synthesis and conclusion on the
presented work. A comprehensive list of references can be found at the end of the work.
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2

RAPID SCREENING OF THE FITNESS LANDSCAPE OF PROTEINS WITH
UNNATURAL AMINO ACIDS USING CELL-FREE PROTEIN SYNTHESIS

Chapters 2 and 3 are adapted from a publication titled “Rapid In Vitro Screening for the
Location-Dependent Effects of Unnatural Amino Acids on Protein Expression and Activity”
(Schinn et al. 2017). The presented work was led by myself in collaboration with former
graduate student colleagues Jeffrey Wu and Andrew Broadbent, and undergraduate students
William Bradley and Ashtyn Groesbeck.

Introduction
Unnatural amino acids (uAA) are a powerful way to functionalize proteins beyond
Nature’s canonical chemistries with site-specific control and minimal mutagenesis (a single
insertion or substitution). Proteins with uAA incorporation (uAA-proteins) are increasingly used
to develop biotherapeutics and biocatalysts (Banerjee et al. 2012; Carter 2011; Pelegri-O’Day et
al. 2014; Tan et al. 2014; Wangler et al. 2010; Yu et al. 2015). In such applications, the uAA
needs to be positioned strategically to both functionalize the protein and preserve its structural
and functional integrity. Here we present a novel method to express, screen and optimize
libraries of uAA-proteins in a rapid manner.
The stop codon suppression method (Section 1.1) has been a powerful and productive
method to site-specifically incorporate numerous types of uAA into proteins (Des Soye et al.
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2015; Quast et al. 2015; Wang et al. 2006). Despite this success, challenges remain. First, the
stop codon mutation for uAA incorporation affects expression yields of uAA-protein. This is due
to incomplete stop codon suppressions caused by native release factors, which compete with
heterologous tRNA for stop codon recognition to result in prematurely terminated, truncated
protein products. The efficiency of stop codon suppression – and consequently the expression
yields of full-length uAA-protein – can vary significantly depending on the suppressed stop
codon location and surrounding sequences. The mechanism for this process is still poorly
understood (Albayrak and Swartz 2013; Quast et al. 2015; Rennell et al. 1991). Second, the
incorporated uAA can adversely affect uAA-protein activity (Wu et al. 2015) presumably by
causing structural perturbations. Such effects depend on the location of the uAA within the
protein’s secondary structure. In short, uAA incorporation affects both the expression and
activity of uAA-proteins in a location-dependent manner. Optimization of such effects are
important for practical applications, but remains challenging to do via rational predictions alone,
despite considerable advances in in silico methods (Dill and MacCallum 2012).
We propose to optimize these effects by producing and screening uAA-proteins in an in
vitro ‘cell-free’ protein synthesis (CFPS) system. The CFPS system employed is derived from
clarified cell-lysate and therefore lacks cellular metabolic processes and a cell membrane. These
characteristics simplify and accelerate the expression and evaluation of uAA-proteins for several
reasons: (1) it foregoes time- and labor-intensive steps of in vivo approaches, such as cellculturing, cloning and product purification; (2) it is easily adaptable to microliter-scale reactions;
(3) it allows direct additions and optimization of external components, such as translational
machineries for uAA incorporation (Bundy and Swartz 2010a; Quast et al. 2015; Smith et al.
2014c) and assay components for in situ measurements; (4) it is capable of producing and
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screening difficult-to-express proteins such as cytotoxic therapeutics (Salehi et al. 2016),
antibodies (Yin et al. 2012) or membrane protein drug targets (Rues et al. 2014); (5) it can be
lyophilized for long-term storage and on-demand use (Smith et al. 2014a).
As a proof-of-concept study, we optimized the incorporation of uAA into T4-lysozyme, a
model protein with a well-characterized structure and extensive mutagenesis studies (Baase et al.
2010; Rennell et al. 1991). A ‘split-GFP’ reporter system (Cabantous et al. 2005) was used to
quantify full-length, uAA-proteins from truncated byproducts resulting from incomplete stop
codon suppression. To this end, a small, non-invasive part of the Green Fluorescent Protein
(GFP), designated as GFP11 (amino acids 214-230) was added at the C-terminus of a protein of
interest. Thus, uAA-incorporated T4-lysozyme- GFP11 products can be selectively detected upon
assembly with the other part of GFP (GFP1-10; amino acids 1-214). The GFP1-10 molecules were
directly added to reaction samples without product purification, resulting in a simplified and
accelerated workflow as compared to previous methods such as autoradiography or product
purification by a C-terminus tag.

Materials & Methods
All materials were purchased from Sigma Aldrich (St. Louis, MO) unless otherwise
specified.

2.2.1

DNA Preparation
For each of the 24 target residues, a mutant variant was created by substituting the target

codon with an amber stop codon (TAG) using Quikchange II mutagenesis protocol (Agilent
Technologies, Santa Clara, CA). All primers were designed to have melting temperatures at
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around 78 °C for parallel mutagenesis reactions. All mutant variant DNA were sequenced
externally (Sequetech Corporation, Mountain View, CA). Vector and primer sequences are
provided in Chapter 3. Plasmids were purified using commercial plasmid mini kits based on
diethylaminoethanol (DEAE) resin for anion-exchange chromatography (Qiagen, Hilden,
Germany).
The GFP11 sequence (Cabantous et al. 2005) was inserted at the C-terminus of a
previously reported T4-lysozyme construct (7LZM.pdb) (Wu et al. 2015) via Quikchange II
mutagenesis protocol (Agilent Technologies, Santa Clara, CA) to the C-terminus of the lysozyme
variant. The non-fluorescent ‘GFP1-10’ was created by mutating two sequential ochre stop codons
(TAATAA) into a previously reported plasmid encoding for superfolder-GFP (Bundy and
Swartz 2010a) after position 213 using Quikchange II mutagenesis protocol. The ‘GFP1-10’
construct was overexpressed in BL21 StarTM (DE3) E. coli strain (Invitrogen, Carlsbad, CA),
mechanically lysed and clarified by centrifugation.

2.2.2

Cell-Free Protein Synthesis
Cell-free extract preparation and cell-free reactions were performed as described

previously (Shrestha et al. 2014; Wu et al. 2015) with Escherichia coli BL21 (DE3) StarTM
(Invitrogen, Carlsbad, CA) harboring the plasmid pEVOL-pPrF, which encodes for the mutated
Methanocaldococcus jannaschii aminoacyl-tRNA synthetase/tRNA pair (Chin et al. 2002). For a
given 20 µL of CFPS reaction, 45 µL of distilled water was first added for even distribution
across the well. Then, 25 µL of lysate-GFP1-10 mixture was added to each reaction, and incubated
at 37 °C for 2.5 hours. Afterward, it was read by the Synergy MX microplate reader (Biotek
Instruments, Winooski, VT) at excitation and emissions wavelengths of 485 nm and 510 nm.
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Enzcheck Lysozyme Assay Kit (ThermoFisher, Waltham, MA, USA) was used to measure
lysozyme activity as previously described (Wu et al. 2015), following manufacturer instructions.
The baseline noise of the yield and activity assays were 600 and 1500 relative fluorescence units,
respectively. The reporting signals of the assays for 0.4 mg/mL of T4-lysozyme-GFP11 were
1500 and 19000 relative fluorescence units respectively, which were used to normalize yield and
activity assay results, as outlined in Figure 2-2C. The described activity assay was found
sensitive and consistent, as well as compatible with the above-described yield assay up to 0.4
mg/ml of T4-lysozyme-GFP11 product (Figures 3-2, 3-3).

2.2.3

Statistical Analysis
Statistical regressions and analyses were carried out using the program JMP (SAS

Institute; Cary, NC, USA). Solvent-accessible surface area (SASA) data was calculated
analytically by the GETAREA method (Fraczkiewicz and Braun 1998) using atomic coordinates,
from 7LZM.PDB. Each amino acid residue’s SASA were normalized by its ‘random coil’ value,
defined as the average SASA of the residue in the tripeptide Gly-X-Gly in an ensemble of 30
random conformations. Obtained values agreed well with calculations by another calculation
method (Cavallo et al. 2003). These and other SASA-predicting algorithms have shown accuracy
and agreement in a model-independent manner for folded proteins (Ausaf Ali et al. 2014).
A more detailed description of materials and methods used is found in Section 3.7.
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Results

2.3.1

Rapid Screening of Model uAA-Protein
Within the resulting T4-lysozyme- GFP11 construct, 24 target residues were selected for

uAA incorporation – N2, D10, G12, K16, T21, I27, H31, K35, S38, A42, S44, K48, N55, D61,
I78, A82, T109, T115, R119, R125, A129, Q141, A146, and T157. Target residues were chosen
at random and evenly distributed throughout the protein, surveying a variety of sequential and
structural contexts. The uAA of choice, p-propargyloxyphenylalanine (pPa), has an alkyne group
for alkyne-azide ‘click reaction’ with wide-ranging applications, including fluorescent probes
(Wang et al. 2014), antibody-based fusion proteins (Hallam et al. 2015), enzyme immobilization
(Wu et al. 2015), and protein-polymer conjugation (Cho et al. 2011). The whole workflow took
approximately 48 hours (Figure 2-1).

Figure 2-1: Rapid screening workflow of uAA-proteins in CFPS.
A rapid, versatile in vitro protein expression platform is assembled from cell-free extract, DNA templates
and cofactors, supplemented by heterologous translational machineries. Product yield and activity are
measured in situ via fluorescence. The workflow is shortened from weeks-long to 48 hours by foregoing
cell culturing and purification. The presented workflow can be further streamlined by using PCR-derived
linear DNA as expression templates, bypassing cloning and DNA purification steps (shaded in grey).
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Figure 2-2: Proof-of-concept screening results of 24 sites in T4-lysozyme.
(A) Selected 24 sites for unnatural amino acid incorporation are marked according to secondary structure
motifs (alpha helix: purple; beta sheet: green; unstructured loop: red). (B) Each site’s yield and activity
values are shown, with favorable incorporation locations (K16, S44, T109) and particularly unfavorable
locations (I78, G12) labeled in orange. These notable sites are also labeled in inset A. (C) Yield and
Activity values were normalized and are unit-less. Normalized uAA-Protein yield for each variant was
calculated by dividing fluorescent results of mutant variants by that of T4-lysozyme with no uAA
incorporation. Specific activities for each variant was calculated by dividing its activity assay result by its
yield assay result, which were then normalized to the specific activity of T4-lysozyme- GFP11. All
experiments were done in triplicates, with error bars representing one standard deviation.

Of the 24 locations (Figure 2-2A), 2 locations (I27 and R125) failed to express at
adequate amounts to be screened. For the remaining 22 expressed variants, the yield of uAAincorporated T4-lysozyme- GFP11 was distributed across a broad range of 10-70% of T4lysozyme- GFP11 yield (Figure 2-2B). As expected, stop codon suppression efficiency during
uAA incorporation was highly dependent on location – for example, T109pPa enjoyed 7-fold
better suppression efficiency than D10pPa. Screening results also confirmed previous reports
which described T4-lysozyme as relatively tolerant to mutations (Baase et al. 2010). Of the 22
positions of uAA, 18 positions retained activity, mostly in the range of 40-70% of T4-lysozymeGFP11 activity. Notably, three incorporation locations (K16pPa, S44pPa, T115pPa) preserved
both activity and yield respectively at >60% and >50% compared to T4-lysozyme- GFP11 (Figure
14

2-2B), making them practical targets for uAA incorporation in protein engineering applications.
Formulae for yield and activity calculations are provided in Figure 2-2C. We also systematically
analyzed potential factors behind these location-dependent effects using our screening data of 24
sites across T4-Lysoyzome, as well as previously published data on 10 sites in superfolder-GFP
(Albayrak and Swartz 2013). Specifically, we looked at other factors potentially influencing
expression efficiency including proximity to N-terminus, nucleic acid sequences, amino acids
charge, codon usage and mRNA.

2.3.2

The ‘Fourth Base’ of Stop Codon Affects uAA-Protein Yield
Based on our analysis, the most significant factor of location-dependent uAA-protein

yields is ‘the fourth base of the stop codon’, or the nucleic acid following the substituting amber
stop codon. The fourth base contributes significantly to peptide release, possibly by interacting
with release factors during recognition (Brown et al. 2015; Poole et al. 1995; Tate et al. 1995).
Our data suggest that fourth base purines suppress amber stop codons more effectively than
pyrimidines counterparts, especially uracil (Figure 2-3A), which agrees well with previous
studies (Poole et al. 1995; Stormo et al. 1986). Indeed, not a single location with fourth base
pyrimidine had uAA-protein yield above 30% of T4-lysozyme- GFP11. Notably, this trend was
strongly reconfirmed by a retroactive analysis of published suppression efficiency data
(Albayrak and Swartz 2013) on 10 variants of uAA-incorporated sfGFP (Figure 2-3B). This new
understanding could help identify unfavorable uAA incorporation sites. The release factor-fourth
base interaction could also be silently mutated to improve incorporation efficiency in the future.
We did not find significant correlation between suppression efficiency and proximity to Nterminus, codon usage, mRNA structure and residue charge (Sections 3.5 and 3.6).
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Figure 2-3: The ‘fourth base’ of stop codon affects suppression efficiency.
Screening data for each uAA location was plotted according to its ‘fourth base’ of the amber stop codon
(x-axis) and uAA-protein yield (y-axis). Data suggests that purines as the ‘fourth base’ resulted in higher
suppression efficiency than pyrimidines with P = 0.0056. P values of combinatorial comparisons between
individual base types are as follows – A:G, 0.7923; A:C, 0.0534; A:U, 0.0260; G:C, 0.1448; G:U, 0.0897;
C:U, 0.7423. T4-lysozyme-GFP11 yield of 0.4 mg/mL was used as the basis of normalization. (B) This
correlation was confirmed by analysis of data previously published (Albayrak et al., 2013) on uAA
incorporation in superfolder-GFP with P = 0.0049. The data for Graph B was derived and adapted from
Figure 4B of (Albayrak et al., 2013).

2.3.3

Structural Features Affect uAA-lysozyme Activity
Beyond production yields, the location optimization of uAA incorporation must also take

into account its impact on activity and structural stability. Numerous mutagenesis studies with
natural amino acids substitutions have shown that T4-lysozyme activity varies significantly
depending on mutation location and structural context (Rennell et al. 1991). Our analysis on 22
successfully expressed T4-lysozyme mutants shows that structural features affect uAA-protein
activity in a significant but difficult-to-predict manner.
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Figure 2-4: Structural features affect uAA-protein activity.
The activities of uAA-incorporated T4-lysozyme constructs appear to be affected by structural features –
(A) the uAA’s distance from the active site region and (B) the uAA location’s local SASA. The
predictive capabilities of the individual correlations are limited (light grey: 95% prediction interval; dark
grey: 95% confidence interval of mean). It is important to note that the SASA value of each amino acid
residue was normalized by its ‘random coil’ value, defined as the average SASA of the residue in the
tripeptide Gly-X-Gly in an ensemble of 30 random conformations. (C) The effect on activity due to the
distance from active site and the SASA for each location were combined as shown, where high activity is
shown on a shaded color scale with dark red being low activity and dark green representing high activity.
(D) The improved predictive capabilities of the combined correlation are also reported.

T4-lysozyme, an inverting glycosidase, is roughly composed of two domains that form a
cleft containing the active site. Specifically, the cleft includes residues E11, D20 and T26, which
play essential roles in the glycolytic process. A detailed exploration of catalytic mechanism of
T4-lysozyme can be found elsewhere (Kuroki et al. 1999). We observed a moderate positive
correlation between preserved activity and distance from catalytic area (Figure 2-4A). For
example, the substitution of the small G12, next to catalytically active residue E11, by the rather
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bulky pPa reduced specific activity to less than 33% of T4-lysozyme- GFP11. The active site was
approximated as the centroid of the three active site residues mentioned above. In addition,
certain salt bridges in T4-lysozyme, such as that of H1-D70, have been demonstrated to play a
significant role in stabilizing the protein (Anderson et al. 1990). This may be a possible
explanation to the 50% reduction in activity shown by H31 substitution by pPa.
Another correlation was also found between reduced activity and substitution at ‘buried’
residues with low solvent-accessible surface area (SASA) (Figure 2-4B). This observation agrees
well with a notable previous study involving single natural amino acid substitutions for each of
the 164 residues of T4-lysozyme (Rennell et al. 1991), as well as other studies (Baase et al. 2010;
Dao-pin et al. 1991). Substitutions at low SASA regions, such as G12, I78, and A146, had the
lowest activity relative to T4-lysozyme- GFP11. Residues that were highly exposed to solvents,
such as S44 and K48, were relatively unaffected by substitutions.
While these two structural features of uAA locations are significant (P = 0.06 and 0.02),
they have low predictive power (R2 = 0.17 and 0.23) as illustrated by its large prediction
intervals (Figure 2-4A and 4B, shaded in light grey). Nevertheless, the two correlations together
could have practical utility in identifying promising or unfavorable incorporation regions.
Indeed, a joint comparison of the two factors shows that the highest-performing locations were
distal from the active site and had high SASA as well (Figure 2-4C, top right, shaded in dark
green). In contrast, locations close to the active site and with low SASA had lower activity
(Figure 2-4C). Such undesirable sites could be identified by in silico calculations of protein
structure and SASA, thereby lowering the number of screening targets. Further, computational
methods could refine target selection in distal, surface-exposed areas as well, by predicting
correlated networks and residue conservation patterns. Proteins without structural or homology
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data - including many potential drug targets and enzymes (Hanson et al. 2010) – would need to
rely more heavily on the screening method alone. The presented analysis has potential to be
applied to proteins beyond T4-lysozyme, although, more screening with diverse protein types is
needed to verify this trend’s consistency.
The presented method is limited by CFPS’s expression yields and assay sensitivities. In
this case, 0.1 μg/μL of T4-lysozyme was sufficient to determine yield and activity. Low-yielding
CFPS reactions can be improved by fine-tuning gene sequence elements, adjusting redox
potential of reaction environment, supplying chaperones or adopting a continuous-exchange
format (Rues et al. 2014; Yin et al. 2012). Difficult-to-express proteins – those involving
multiple disulfide bonds, complex folding requirements, or multimeric structure –may require
systematic and combinatorial optimizations across several parameters.

2.3.4

Conclusion
In summary, unnatural amino acids can be used to uniquely and site-specifically

functionalize proteins as sophisticated and effective biotherapeutics and biocatalysts. To
facilitate such functionalization, we have developed a flexible in vitro platform to accelerate and
simplify the expression and screening of uAA-containing proteins, as compared to traditional
technologies. As a proof-of-concept experiment, 24 uAA locations were screened in T4lysozyme for optimal expression and activity in circa 48 hours. Screening results identified
sequential and structural features as important factors to uAA-protein yield and activity.
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3

SUPPLEMENTARY MATERIAL TO CHAPTER 2

Annotated Sequence of pY71-Lysozyme-GFP11 Construct
GGATCCTGCAGTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGT
GGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATA
CTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTA
ATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGA
TAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGA
GATACCTACAGCGTGAGCATTGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGC
AGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCG
CCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAACGAATTCAGATCTAAT
ACGACTCACTATAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACATA
TGAATATATTTGAAATGTTACGTATAGATGAAGGTCTTAGACTTAAAATCTATAAAGACACAGAAGGCTATTACACT
ATTGGCATCGGTCATTTGCTTACAAAAAGTCCATCACTTAATGCTGCTAAATCTGAATTAGATAAAGCTATTGGGCG
TAATACTAATGGTGTAATTACAAAAGATGAGGCTGAAAAACTCTTTAATCAGGATGTTGATGCTGCTGTTCGCGGAA
TTCTGAGAAATGCTAAATTAAAACCGGTTTATGATTCTCTTGATGCGGTTCGTCGCGCTGCATTGATTAATATGGTT
TTCCAAATGGGAGAAACCGGTGTGGCAGGATTTACTAACTCTTTACGTATGCTTCAACAAAAACGCTGGGATGAAGC
AGCAGTTAACTTAGCTAAAAGTAGATGGTATAATCAAACACCTAATCGCGCAAAACGAGTCATTACAACGTTTAGAA
CTGGCACTTGGGACGCGTATAAAAATCTACGGGACCACATGGTTCTGCACGAATATGTGAATGCGGCAGGTATTACG
TAAGTCGACCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAA
CCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGCCAATTCTGATTAGAAAAACTCATCGAGCAT
CAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAG
AAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATA
CAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGA
GAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCG
CATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTA
CAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTC
TTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAAT
GCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACG
CTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTG
CCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCTTCGAGCAAG
ACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCATGAT
GATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAACGT

Notes about above sequence:
Green = GFP11
Yellow = T4-Lysozyme (7LZM.pdb)
Light Blue = T7 promoter or terminator
GTCGAC = SalI CUT SITE
CATATG = NdeI Cut site
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Mutagenesis Primer Sequences
Table 1 shows forward primers used in PCR mutagenesis reactions for substituting
various residues throughout lysozyme with the amber stop codon. Primers were designed to have
comparable melting temperatures close to 60 C° for parallel reactions.
Table 3-1: Mutagenesis Primers (Forward)
Residue

Position

Forward Primers Sequence

N

2

GGAGATATACATATGTAGATATTTGAAATGTTACGTATAGATGAAGG

58.8

D

10

GAATATATTTGAAATGTTACGTATATAGGAAGGTCTTAGACTTAAAATCTATAAAGAC

60.2

G

12

GTTACGTATAGATGAATAGCTTAGACTTAAAATCTATAAAGACACAG

58.9

K

16

GGTCTTAGACTTTAGATCTATAAAGACACAGAAGGC

58.9

I

27

GCTATTACACTTAGGGCATCGGTCATTTGC

60.9

H

31

CTATTGGCATCGGTTAGTTGCTTACAAAAAGTCC

60.7

S

38

GCTTACAAAAAGTCCATAGCTTAATGCTGCTAAATCTG

60.6

A

42

GTCCATCACTTAATGCTTAGAAATCTGAATTAGATAAAGC

58.8

S

44

CACTTAATGCTGCTAAATAGGAATTAGATAAAGCTATTGG

58.8

K

48

GCTAAATCTGAATTAGATTAGGCTATTGGGCG

58.8

N

55

GGCGTAATACTTAGGGTGTAATTACAAAAGATGAGG

59.7

D

61

CTAATGGTGTAATTACAAAATAGGAGGCTGAAAAACTC

59

I

78

CTGTTCGCGGATAGCTGAGAAATGC

60

A

82

CGCGGAATTCTGAGAAATTAGAAATTAAAACCGG

59.6

R

95

CTTGATGCGGTTTAGCGCGC

59.9

T

109

CAAATGGGAGAATAGGGTGTGGCAG

59.7

A

112

GGAGAAACCGGTGTGTAGGGATTTACTAAC

T

115

GTGGCAGGATTTTAGAACTCTTTACGTATGC

59.1

R

119

GGATTTACTAACTCTTTATAGATGCTTCAACAAAAACGC

59.3

R

125

GCTTCAACAAAAATAGTGGGATGAAGCAGC

60.3

Q

141

GTAGATGGTATAATTAGACACCTAATCGCGC

58.2

A

146

CACCTAATCGCTAGAAACGAGTCATTACAACG

T

157

CGTTTAGAACTGGCTAGTGGGACG
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Tm [C°]

60

60
59.2

Table 3-2: Mutagenesis Reverse Primers
Residue

Position

Reverse Primers Sequence

N

2

CCTTCATCTATACGTAACATTTCAAATATCTACATATGTATATCTCC

58.8

D

10

GTCTTTATAGATTTTAAGTCTAAGACCTTCCTATATACGTAACATTTCAAATATATTC

60.2

G

12

CTGTGTCTTTATAGATTTTAAGTCTAAGCTATTCATCTATACGTAAC

58.9

K

16

GCCTTCTGTGTCTTTATAGATCTAAAGTCTAAGACC

58.9

I

27

GCAAATGACCGATGCCCTAAGTGTAATAGC

60.9

H

31

GGACTTTTTGTAAGCAACTAACCGATGCCAATAG

60.7

S

38

CAGATTTAGCAGCATTAAGCTATGGACTTTTTGTAAGC

60.6

A

42

GCTTTATCTAATTCAGATTTCTAAGCATTAAGTGATGGAC

58.8

S

44

CCAATAGCTTTATCTAATTCCTATTTAGCAGCATTAAGTG

58.8

K

48

CGCCCAATAGCCTAATCTAATTCAGATTTAGC

58.8

N

55

CCTCATCTTTTGTAATTACACCCTAAGTATTACGCC

59.7

D

61

GAGTTTTTCAGCCTCCTATTTTGTAATTACACCATTAG

59

I

78

GCATTTCTCAGCTATCCGCGAACAG

60

A

82

CCGGTTTTAATTTCTAATTTCTCAGAATTCCGCG

59.6

R

95

GCGCGCTAAACCGCATCAAG

59.9

T

109

CTGCCACACCCTATTCTCCCATTTG

59.7

A

112

GTTAGTAAATCCCTACACACCGGTTTCTCC

T

115

GCATACGTAAAGAGTTCTAAAATCCTGCCAC

59.1

R

119

GCTGCTTCATCCCACTATTTTTGTTGAAGC

59.3

R

125

GCTAAGTTAACTGCCTATTCATCCCAGC

60.3

Q

141

GCGCGATTAGGTGTCTAATTATACCATCTAC

58.2

A

146

CGTTGTAATGACTCGTTTCTAGCGATTAGGTG

T

157

CGTCCCACTAGCCAGTTCTAAACG
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Tm [C°]

60

60
59.2

All Mutation Sites Labeled in T4-Lysozyme

Figure 3-1: All mutation sites labeled in T4-lysozyme.
Selected 24 sites for unnatural amino acid incorporation. The sites are marked according to secondary
structure motifs (alpha helix: blue; beta sheet: green; unstructured loop: red).

Validation of Assays
The consistency and validity of the presented yield and activity assay was observed up to
0.4 mg/mL. First, 740 μg of T4-lysozyme-GFP11 was expressed in CFPS and measured by
scintillation counting. The product was diluted with cell-free reaction mixture over the range 0 –
0.4 mg/mL, and assayed for yield and activity as described. The result shows that split-GFP
fluorescence corresponds linearly with product yield between 0.1 – 0.4 mg/mL (Figure 3-2).
Also, the specific activity of the variants, defined the unit-less ratio between fluorescence values
from activity assay and yield assay, remained consistent throughout the approximately the same
range (Figure 3-3). CFPS reactions from the rapid screening yielded approximately 0.2 mg/mL
of full-length, pPa-incorporated lysozyme variant product. Therefore, the presented assays are
appropriate and accurate in measuring yield and activity of lysozyme variants. All reactions
were carried out in triplicates.
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Figure 3-2: Validation of yield assay.

Figure 3-3: Validation of activity assay.

Analysis of Potential Factors on Stop Codon Suppression Efficiency
Multiple factors involved in transcription and translation were analyzed in connection
with suppression efficiency of amber stop codon. Some factors had inconclusive or negligible
correlation with suppression efficiency. Parts of their analyses are shown here for reference.

3.5.1

Proximity to N-terminus
Previous studies have suggested proximity of amber stop codon to N-terminus could

affect stop codon suppression efficiency (Ezure et al. 2014; Goerke and Swartz 2009). We did
not find significant correlation between suppression efficiency and uAA proximity to N-terminus
in lysozyme variants (Figure 3-4), similarly to what was found with GFP variants previously
(Albayrak and Swartz 2013). However, it is possible that such effect become more pronounced
with larger proteins or certain structures. For example, proximity to N-terminus was positively
correlated in a membrane protein that was two-fold larger than lysozyme and GFP (Ezure et al.
2014).
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Figure 3-4: Proximity to N-terminus does not affect suppresion efficiency.

3.5.2

Rare Codons
The codon usage of a sequence can influence translational speed, and even induce

ribosomal stalling. Therefore, codon usage of sequences surrounding the target codon could
impact the suppression efficiency. One to three codons upstream and downstream of the target
codon, as well as the target codon itself, were analyzed for correlations between codon usage and
suppression efficiency, but no significant correlation was found. Part of the analysis is shown
below for reference (Figure 3-5).

Figure 3-5: Codon usage effects on suppression efficiency
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Notably, the presence of one or more ‘rare’ codons across the two codons preceding
target codon was positively correlated to suppression efficiency of amber stop codon, albeit
relatively weakly (P=0.0644). Rare codons were defined as codons with <10% E. coli Class II
codon usage. This trend was particularly strong when the target codon was located in the latterhalf of the protein (P <0.01). However, the significance of this trend is ambiguous, given its lack
of mechanistic explanation (Figure 3-6).

Figure 3-6: Rare codon effects on suppression efficiency.

3.5.3

Structure of mRNA
The structure of mRNA can have a significant impact on transcription and translation.

The mRNA structure of T4 lysozyme was simulated and analyzed in terms of paired and
unpaired bases. Given a sequence of mRNA, paired bases and unpaired bases were given values
of 1 and 0, respectively. These values were summed up as the total amount of base-pairings with
the sequence. Such analysis was done for 3, 6 and 9 bases both upstream and downstream of the
target codon. Analysis results show that there was no significant correlation between amounts of
mRNA base-pairing and stop codon suppression efficiency (Figure 3-7; dark grey: 95%
confidence interval of mean; light grey: 95% prediction interval).
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Figure 3-7: mRNA structure effects on suppression efficiency.

Analysis of Potential Factors on Activity of Proteins with Unnatural Amino Acids
Multiple structural factors were analyzed in connection with specific enzymatic activity.
Some factors had inconclusive or negligible correlation with suppression efficiency. Parts of
their analyses are shown here for reference.

3.6.1

Secondary Structures
Incorporations of pPa in alpha helix structures versus random coil regions did appear to

have a statistically different effect on activity (Figure 3-8). Also, the effects of incorporation in
beta sheets is inconclusive.
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Figure 3-8: Secondary structure effects on suppression efficiency

3.6.2

Net Charge of Regions Neighboring Incorporation Site
The charge of a residue was measured by the pKa of its functional group. The net pKa of

residues preceding and following the incorporation of pPa were analyzed in relation to specific
enzymatic activity, with no significant correlation found. A graphical representation of some of
the analysis is provided in Figure 3-9 (Dark grey: 95% confidence interval of mean; light grey:
95% prediction interval).

Figure 3-9: Structural charge effects on uAA-protein activity
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Detailed Materials & Methods
All materials were purchased from Sigma Aldrich (St. Louis, MO) unless otherwise
specified.

3.7.1

Plasmid Construction & Purification
A mutated GFP11 sequence (RDHMVLHEYVDAAGIT; added mutation N225D is

bolded)(Cabantous et al. 2005) was inserted at the C-terminus of a previously reported T4lysozyme construct (7LZM.pdb) (Wu et al. 2015) via Quikchange II mutagenesis protocol
(Agilent Technologies, Santa Clara, CA) to the C-terminus of the lysozyme variant (Primer
sequence, with GFP11 sequence in bold - Forward:
GCGTATAAAAATCTACGUGAUCAUAUGGUGCUGCAUGAAUAUGUGGAUGCGGC
GGGCAUUACCTAAGTCGACCGGCTG; Reverse:
CAGCCGGTCGACTTAGUTGCCCGCCGCUTCCUCUTUTTCUTGCUGCUCCUTUTG
UTCUCGTAGATTTTTATAC). The N225D mutation lowered the fluorescence intensity of
split-GFP system, so as to not interfere with activity assay signals at neighboring fluorescence
wavelengths.
Within the resulting T4-lysozyme-GFP11, 24 target residues were selected for uAA
incorporation – N2, D10, G12, K16, T21, I27, H31, K35, S38, A42, S44, K48, N55, D61, I78,
A82, T109, T115, R119, R1125, A129, Q141, A146, and T157. Target residues were chosen at
random and evenly distributed throughout the protein, surveying a variety of sequential and
structural contexts. For each target residue, a mutant variant was created by substituting the
target codon with an amber stop codon (TAG) using Quikchange II mutagenesis protocol
(Agilent Technologies, Santa Clara, CA). All primers were designed to have melting
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temperatures at around 78 °C for parallel mutagenesis reactions. All mutant variant DNA were
sequenced externally (Sequetech Corporation, Mountain View, CA). Primer sequences for
mutagenesis are provided in Chapter 4. Plasmids were purified using commercial plasmid mini
kits based on diethylaminoethanol (DEAE) resin for anion-exchange chromatography (Qiagen,
Hilden, Germany).

3.7.2

Split-GFP Reporter System
Two sequential ochre stop codons (TAATAA) were mutated into a previously reported

plasmid encoding for superfolder-GFP (Bundy and Swartz 2010a) after position 213 using
Quikchange II mutagenesis protocol. The resulting plasmid encoded for the non-fluorescent
‘GFP1-10’ consisting of the first 10 out of eleven 11 beta sheets that form GFP’s beta-barrel
structure, as used in the split-GFP reporting system (Cabantous et al. 2005). The plasmid was
transformed into BL21 StarTM (DE3) E. coli strain (Invitrogen, Carlsbad, CA). The transformed
cells were fermented in 1 L of Luria Bertani (LB) broth using 2.5 L Tunair fully baffled shake
flask (Shelton Scientific, Shelton, CT) at 37 °C and constant shaking at 280 rpm. At optical
density of 0.6, isopropyl-β-D-thiogalactoside (IPTG) was added at a final concentration of 1mM
to induce expression of OPT1-10. After 16 hours of continued fermentation, cells were pelleted
at 28,000 × g at 4 °C for 15 min. The resulting pellet was suspended in 10 mL of cold S30 buffer
(10 mM Tris acetate, pH 8.2; 16 mM potassium acetate; 14 mM magnesium acetate) per gram of
wet cell. Centrifugation and resuspension was repeated at 1 ml S30 buffer per gram of cell. The
cells were disrupted in a high pressure homogenizer at constant pressure of 2000 psi, resulting in
a lysate containing highly concentrated GFP1-10, using the Emusiflex B-15 French Press
(Avestin, ON, Canada) method described previously (Shrestha 2012). The result was a clarified
lysate with overexpressed GFP1-10.
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3.7.3

Rapid In Vitro Expression & Screening
Cell-Free Protein Synthesis
Cell-free extract was prepared as described in previous works (Shrestha et al. 2014).

Specifically, Escherichia coli extract was prepared using a BL21 (DE3) StarTM strain
(Invitrogen, Carlsbad, CA) harboring the plasmid pEVOL-pPrF plasmid, which encodes for
Methanocaldococcus jannaschii aminoacyl-tRNA synthetase/tRNA pair capable of recognizing
and inserting unnatural amino acid p-propargyloxyphenylalanine.
Cell-free reactions were performed as described previously, including the addition of
2mM of pPa and 3 mg/ml of heterologous aminoacyl-tRNA Synthetase (Bundy and Swartz
2010a). All CFPS reactions were incubated at 30 °C for 16 hours overnight. After overnight
incubation, the reactions were assayed for yield and activity immediately.
Yield & Activity Assays
For a given 20 µL of CFPS reaction, 45 µL of distilled water was first added for even
distribution across the well. Then, 25 µL of lysate-GFP1-10 mixture was added to each reaction.
This was incubated at 37 °C for 2.5 hours. Afterward, it was read by the Synergy MX microplate
reader (Biotek Instruments, Winooski, VT) at excitation and emissions wavelengths of 485 nm
and 510 nm. Normalized efficiencies of stop codon suppression for each variant was calculated
by dividing fluorescent results of mutant variants by that of T4-lysozyme-GFP11. The reported
yield assay was found sensitive and consistent across 0.07 to 0.7 mg/ml of T4-lysozyme- GFP11
product, , with concentrations confirmed by previously reported C-14 Leucine radiolabeling
method (Wuu and Swartz 2008b).
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Enzcheck Lysozyme Assay Kit (ThermoFisher, Waltham, MA, USA) was used to
measure lysozyme activity, where 3 µg of fluorescein-labeled Micrococcus lysodeikticus cellwall substrate was suspended in 45 µL of assay reaction buffer at 37 °C. The resulting mixture
was added to completed CFPS reactions, which were already assayed for yield with the lysateGFP1-10 mixture as described above. The resulting fluorescence was read by the Synergy MX
microplate reader at excitation and emissions wavelengths of 494 nm and 518 nm. Normalized
efficiencies of stop codon suppression for each variant was calculated by dividing its activity
assay result by its yield assay result. Such specific activity was further normalized to the specific
activity of T4-lysozyme- GFP11. The described activity assay was found sensitive and consistent,
as well as compatible with the above-described yield assay up to 0.7 mg/ml of T4-lysozymeGFP11 product.

3.7.4

Validation of Yield Assay & Activity Assay
The consistency and validity of the presented yield and activity assay was observed up to

0.4 mg/mL. First, 740 μg of T4-lysozyme-GFP11 was expressed in CFPS and measured by
scintillation counting. The product was diluted with cell-free reaction mixture over the range 0 –
0.4 mg/mL, and assayed for yield and activity as described. The result shows that split-GFP
fluorescence corresponds linearly with product yield between 0.1 – 0.4 mg/mL (Figure 7-1).
Also, the specific activity of the variants, defined the unit-less ratio between fluorescence values
from activity assay and yield assay, remained consistent throughout the approximately the same
range (Figure 7-2). CFPS reactions from the rapid screening yielded approximately 0.2 mg/mL
of full-length, pPa-incorporated lysozyme variant product. Therefore, the presented assays are
appropriate and accurate in measuring yield and activity of lysozyme variants. All reactions
were carried out in triplicates.
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3.7.5

Statistical Analyses
Statistical regressions and analyses was carried out using the program JMP (SAS

Institute; Cary, NC, USA). Escherichia coli Class II codon usage data was derived from the
works of Hénaut et al. (Henaut and Danchin 1996b). Secondary structures of mRNA was
simulated using the web-based RNA structure software (Bellaousov et al. 2013). Solventaccessible surface area (SASA) data was predicted analytically using 7LZM.PDB as input
(Fraczkiewicz and Braun 1998). Each amino acid residue’s SASA were normalized by its
‘random coil’ value, defined as the average SASA of the residue in the tripeptide Gly-X-Gly in
an ensemble of 30 random conformations.
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4

OPTIMIZATION OF LINEAR DNA CONCENTRATION AND PURIFICATION
FOR CELL-FREE SYSTEMS

Chapters 4 and 5 are partially adapted from publications titled “Protein Synthesis Directly
from PCR: Progress and Applications of Cell-free Protein Synthesis with Linear DNA” (Schinn
et al. 2016) and “Rapid In Vitro Screening for the Location-Dependent Effects of Unnatural
Amino Acids on Protein Expression and Activity” (Schinn et al. 2017). The presented work was
led by myself in collaboration with former graduate student colleagues Jeffrey Wu and Andrew
Broadbent. Undergraduate students William Bradley and Ashtyn Groesbeck also significantly
contributed to this work.

Introduction
Recent advances in high-throughput methods have produced an abundance of sequence
information, whose functional characterization have been lagging behind. This growing gap
accentuates the need for a rapid and robust protein expression and screening platform. CFPS
systems have the advantageous possibility to utilize linear DNA as expression templates, thanks
to the lack of intracellular metabolism and regulation. Such linear expression templates (LET)
can be produced via PCR in hours, simplifying and accelerating large throughput screenings
(Figure 4-1).
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Traditionally LET have suffered from low CFPS expressions due to their vulnerability to
latent nucleases in the cell-free environment, such as exonuclease V or RecBCD DNAse
complex (Pratt et al. 1981; Yang et al. 1980). Previously, the nuclease inhibitor Gam protein
from bacteriophage λ has been explored successfully (Shrestha et al. 2014; Sun et al. 2013; Yin
et al. 2012). However, such nuclease inhibitors are not widely available and require additional
steps of synthesis, purification and storage. Other methods, such as genetic engineering (MichelReydellet et al. 2005) or selective removal of native nucleases (Seki et al. 2009), also complicate
and lengthen the screening workflow (Section 5.2).
Here we explore a simpler alternative solution to maintain LET stability by optimizing
LET reaction concentrations and purification procedure. To demonstrate the viability of this
method, we successfully replicate a screening experiment from Chapter 2 using LET with an
accelerated timeframe.

Figure 4-1: Rapid expression and screening of proteins in LET-based CFPS.
(A) LET-based CFPS simplifies and accelerates protein synthesis workflows for high-throughput
screening applications, compared to plasmid-based CFPS or in vivo methods. (B) A major technical
challenge of LET-based CFPS is the degradation of LET by native nucleases. Significant strides have
been made to overcome this challenge. (C) The components of LET-based CFPS can be quickly
assembled and customized as a versatile tool for many application fields.
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Methods

4.2.1

Linear DNA Production
Linear DNA templates (LET) were produced by amplifying gene sequences from a

plasmid template using amplification primers. PCR reactions were assembled from 2 ng of
plasmid template, 0.5 µM forward primer, 0.5 µM reverse primer, 0.2 mM dNTP, 1 µL Pfu DNA
polymerase, and 5 µL 10x Pfu buffer (200 mM Tris-HCl, pH 8.8; 20 mM magnesium sulfate;
100 mM potassium chloride; 100 mM ammonium sulfate; 1% (vol/vol) Triton X-100; 1 mg/mL
nuclease-free bovine serum albumin). All PCR reactions were adjusted to a final volume of 50
µL with water. The resulting PCR products were analyzed on electrophoresis gel and purified
using the following methods. The primer sequences used in LET amplification are as follows:
Forward,
ATAAAAAAGCATTGCTTATCAATTTGTTGCAGGTTTCGCCACCTCTGACTTGAGCGT;
Reverse,
CTCACCGAGGCAGTTCCATAGGATGGCAATAAAAAAGCATTGCTTATCAATTTGTTG
CA)

4.2.2

Purification by Silica Adsorption
Linear DNA PCR products were purified using commercial DNA purification kits based

on silica adsorption following manufacturer instructions (Zymo Research, Irvine, CA, USA).

4.2.3

Purification by Gel Filtration
A Sephadex resin slurry was prepared by combining 2 g of Sephadex G-50 in 30 mL of

distilled water. The resin was incubated in 4 °C overnight for hydration. For a given 30 µL or 50
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µL of PCR reaction, 400 µL of well-mixed slurry was placed Costar SpinX filter and centrifuged
for 1 min at 1,300 × g to form an approximately 20 µL-sized sloped resin bed. The spin column
and the resin bed was transferred to a new 1.5 µL Eppendorf tube (VWR International, Radnor,
PA, USA), and centrifuged again for 1 min at 1,300 × g. The flow-through was then stored at
4 °C. The purified LET was quantified via a microplate reader, as above.

4.2.4

Purification by Alcohol-Salt Precipitation
400 µL of PCR reaction was mixed with 180 µL of ammonium acetate and 580 µL of

isopropyl alcohol, and cooled at -20 °C for 15 min. The mixture was then centrifuged at 13,000 ×
g for 10 min at 4 °C. The resulting pellet was often not visible or hard to see. The supernatant
was gently decanted and residual liquid was carefully pipetted while minimizing the disturbing
of the pellet. The pellet was then washed with 500 µL of 95% ethanol at -20 °C, and was
centrifuged at 13,000 × g for 5 min at 4 °C. Again, the supernatant was gently decanted and
residual ethanol was carefully pipetted out. Pellet was resuspended in 50 µL of distilled water
with gentle agitation. The purified LET was quantified using 260 nm absorbance with a
SYNERGY MX microplate reader (BioTek Instruments, Winooski, VT, USA).

4.2.5

Cell-Free Protein Synthesis
Cell-free extract was prepared as described in previous works (Shrestha et al. 2014).

Specifically, Escherichia coli extract was prepared using a BL21 (DE3) StarTM strain
(Invitrogen, Carlsbad, CA) harboring the plasmid pEVOL-pPrF plasmid, which encodes for
Methanocaldococcus jannaschii aminoacyl-tRNA synthetase/tRNA pair capable of recognizing
and inserting unnatural amino acid p-propargyloxyphenylalanine (pPa).
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Cell extract was prepared as described before. Cell-free reactions were performed as
described previously, including the addition of 2mM of pPa and 3 mg/ml of heterologous
aminoacyl-tRNA Synthetase (Bundy and Swartz 2010a). Further, LET from unpurified PCR
reactions were added to CFPS reaction at final concentrations of approximately 30 ng/μL. All
CFPS reactions for screening mutant variants were accompanied by two control reactions – a
negative control reaction without expression templates, and a positive control with LET
encoding T4-lysozyme-GFP11. All CFPS reactions were incubated at 30 °C for 16 hours
overnight. Lower reaction temperature has been suggested to decrease nuclease activity, and
thereby increase yields of LET-based CFPS (Seki et al. 2008; Shrestha et al. 2014). After
overnight incubation, the reactions were assayed for yield and activity immediately.

Results

4.3.1

Characterization of Purification of Linear DNA
Here, four different PCR product purification methods were evaluated for compatibility

with an LET-based CFPS system. Common commercial kits provide quick and easy DNA
purification via silica adsorption, but utilize buffers containing chaotropic salts such as
Guanidine Hydrochloride (Gu-HCl) which can disrupt protein structures and in vitro ribosomal
translation (Section 5.4). Silica-adsorption kits using Gu-HCl have been widely applied to LET
preparation (Heinrich et al. 2011; Shrestha et al. 2014; Sun et al. 2013; Yin et al. 2012).
However, the potentially inhibitory effects of Gu-HCl on LET-driven CFPS have not been
directly evaluated. In response, we evaluated LET purification via silica adsorption and three
other Gu-HCl-free purification methods: alcohol-salt precipitation, gel filtration and no
purification (Figure 4-2).
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For all four examined purification methods, LET at optimized concentrations produced
plasmid-level yields. In the silica adsorption method, the presence of GuHCl in the binding
buffer did not affect CFPS activity, suggesting adequate removal of potentially inhibitory salts
from purified LET. The slight reductions in yield for gel filtrated and non-purified LET may be
due to incomplete removal of PCR reaction buffer and salts. Both silica adsorption and gel
filtration provided rapid, easy purification workflows with satisfactory recovery rates (<30 min,
40 - 50% recovery). In contrast, alcohol-salt precipitation was challenging to execute in parallel
for large numbers of samples due to delicate and translucent DNA pellets at lower DNA
concentrations. PCR reaction products introduced directly and wholly to CFPS reactions without
any purification is the simplest, quickest and least expensive method.

GFP Yield [mg/mL]

2

1.5

1

0.5

0

Plasmid DNA
Control

No Purification Silica Adsorption

Gel Filtration

Alcohol-Salt
Precipitation

Purification Method

Figure 4-2: LET purification methods are found compatible with CFPS.
All evaluated purification methods produced LET with performances similar to plasmid DNA. This
shows that CFPS is robust enough against some contaminates at certain amounts, including Gu-HCl, PCR
reagents and buffers.
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4.3.2

Increased LET Concentrations Preserves Protein Synthesis Yields
Here we demonstrate that simply increasing the template concentrations significantly

conserves yields of LET-based CFPS systems. We achieved plasmid-level CFPS yields by
increasing LET concentrations some thirty fold, from 10 nM to 360 nM (Figure 4-3). We also
observed that an upfront increase in LET concentration was more effective in CFPS yield
preservation than serial additions of LET supply every 30 minutes throughout the reaction
duration. This suggests that critical amounts of mRNA transcription occur at the beginning of the
CFPS reaction. The presented method preserves yields of LET-based CFPS without complicating
the workflow, lending itself well to parallel, large throughput screening experiments.
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Figure 4-3: Increased concentrations of LET improve CFPS yields.
Lower CFPS yield due to LET degradation can be overcome by increasing LET concentrations, resulting
in plasmid-level yields (green). CFPS yields were higher LET were added upfront during reaction
assembly (yellow), rather than added serially throughout the reaction duration (orange, asterisked), given
the same LET concentration (360 nM).
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4.3.3

Accelerated Screening Using Linear DNA
The screening workflow presented in Chapter 2 could be further accelerated and

simplified by using LET, thereby circumventing transformation and plasmid template
preparation steps. The resulting workflow was completed in approximately 24 hours (Figure 2-2,
circumvented steps are shaded in grey). Screening results agreed well with data from plasmidbased control experiments (Figure 4-4). For 18 of the 22 locations, the difference in means
between the two methods was less than the plasmid dataset’s 95% confidence interval and the
remaining four differed modestly (<15% specific activity). This suggests that LET-based CFPS
can perform similarly to plasmid-based systems, but with a simpler, faster workflow.

Figure 4-4: LET-based screening performs comparably to plasmid-based method.
Linear DNA templates in CFPS produce comparable screening results to plasmid DNA, as shown by
activity data from the 22 expressed uAA locations, out of a total of 24 investigated sites. All experiments
were done in triplicates, with error bars representing one standard deviation.
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Conclusion
Increasing LET concentrations is a quick and simple way to side-step lower CFPS yields
due to linear DNA degradation. Such increase should be done upfront during reaction assembly
for optimal results. Such LET can be rapidly produced in PCR and added to CFPS without
purification with minimal reduction in product yield. To demonstrate the viability of LET, a
screening experiment involving uAA incorporation was successfully replicated using LET
instead of plasmid templates in CFPS. The LET-based workflow was shorter and simpler than its
plasmid-based alternative. This confirms the usefulness of LET-based CFPS systems in
screening applications.
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5

SUPPLEMENTARY MATERIAL TO CHAPTER 4

Growth of LET Utilization
The past decade has seen significant growth in yields of LET-driven CFPS, propelling it
as a powerful tool for high-throughput production and screening of protein products (Figure 5-1).
For example, over the course of a decade the yield of antibody fragments in LET-based CFPS
has increased more than 100-fold, approaching 103 μg/ml yields (He and Taussig 2001; Yin et al.
2012).
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Figure 5-1: Growth in yields of LET-based CFPS.
Growth in yields of LET-based CFPS has been achieved thanks to technological innovations, as
illustrated by a survey of over 30 reported experiments (Ahn et al. 2005; Burks et al. 1997; Haberstock et
al. 2012; Han et al. 2006; He et al. 2008b; He and Taussig 2001; Kwon et al. 2010; Lesley et al. 1991;
Michel-Reydellet et al. 2005; Seki et al. 2009; Seki et al. 2008; Shrestha et al. 2014; Sitaraman et al.
2004; Stech et al. 2014; Stech et al. 2013; Woodrow et al. 2006; Wu et al. 2007; Yin et al. 2012). Green
Fluorescent Protein and antibody fragments are highlighted in green and red, respectively.

43

The clear trend of yield increase is partially due to a spectacular growth of cell-free
systems in general, fueled by a better understanding of inner metabolic networks (Kim and
Swartz 1999; Kim and Swartz 2001), methodological optimizations of reaction conditions
(Calhoun and Swartz 2006; Jewett and Swartz 2004; Kim and Swartz 2000) and extract
preparation methods (Kwon and Jewett 2015; Yin et al. 2012). Comparable efforts to specifically
improve LET-based CFPS to inhibit nuclease attack against LET have also enjoyed success.

An Overview of Existing Strategies of Stabilizing Linear DNA in E. coli-based CellFree Systems

5.2.1

Genomic Alteration
Various efforts have targeted the RecBCD complex by deleting the genes for its

individual subunits. Unfortunately, because native exonucleases often play a critical role in
intracellular recombination processes, cell growth is retarded. For example, while a ΔrecB strain
lacks the dominant nuclease RecB, its growth is severely retarded (Yu et al. 1998), thus limiting
the strain’s CFPS potential. In contrast, a ΔrecD mutation did not affect growth, but the strain
did not significantly improve LET survivability either (Michel-Reydellet et al. 2005). To
overcome this problem, the recBCD operon was replaced with the bacteriophage λ red
recombination system, for which an improved in vivo recombination activity with linear DNA
has already been demonstrated (Murphy et al. 2000). The resulting extract did not suffer from
slow growth and improved protein expression seven-fold to near plasmid levels (MichelReydellet et al. 2005).
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In one interesting study, nuclease components RecD and PNPase were modified to have a
streptavidin-binding sequencewithout affecting cell growth. As part of extract preparation, these
nucleases were selectively removed via specific affinity to streptavidin. The study reports
plasmid-level yield (Seki et al. 2009), but this process does increase the time and labor cost of
extract preparation.

5.2.2

Inhibition of Nucleases
As an alternative to genomic engineering, molecular inhibitors can be used to target

native exonucleases. These inhibitors’ activities need to be specific enough to target nuclease but
not inhibit other molecules necessary for CFPS. For example, the Gam protein from
bacteriophage λ has been identified as an effective inhibitor of RecBCD nuclease. A truncated
version of this protein, GamS, has been employed to successfully inhibit nuclease activity in
CFPS and achieve close to plasmid-level yields (Sitaraman et al. 2004; Sun et al. 2013; Yin et al.
2012). The GamS protein can be stored with DMSO as a cryoprotectant which is non-toxic to
CFPS activity (Sun et al. 2013). Small molecule inhibitors have also been used to target RecBCD
in CFPS with moderate success (Shrestha et al. 2014).
One simple and straightforward solution is a lower temperature, which has been explored
in general plasmid-based CFPS with success, especially in context where “nonstandard
components” are added (Goerke and Swartz 2009; Smith et al. 2014b). Specifically for LETbased systems, nuclease activity is decreased at lower temperatures, resulting in increased yields
(Seki et al. 2008).
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5.2.3

Alteration of Template Geometry
Lastly, template preparation can include steps to improve survivability in LET-CFPS. For

example, T7 terminator sequence, poly(G) sequence, mini-hairpin sequences and other
noncoding sequences have been explored to improve yield (Ahn et al. 2005; Sun et al. 2013).
One creative study addressed the solubility limit of LETs and their vulnerability to nuclease
degradation simultaneously by crosslinking LETs into a hydrogel. This hydrogel sustained a
CFPS reaction that produced up to 5 mg/mL of functional protein (Park et al. 2009).

Applications
Current scientific and engineering endeavors tackle complex and difficult tasks such as
drug development, biocatalyst discovery and synthetic gene circuit design. Such efforts are
guided by “bounded rationality”, relying on both scientific insight and trial-and-error testing.
Both approaches depend upon the ability to make and evaluate protein in a simple and timely
fashion. This renders LET-based CFPS as an appealing tool for high-throughput screening
applications. It has already begun to prove its usefulness in various arenas, as demonstrated by
the following examples.

5.3.1

Cloning-Independent Functional Genomics
Recent advances in sequencing technology have created a wealth of genomic information

which wait to be translated to deeper insights into protein functions and protein-protein
interactions. In order to help keep pace with the swell of sequence data, high-throughput protein
synthesis methods must analyze complex protein behaviors in tandem with computational tools.
By doing this, CFPS would accelerate the discovery of novel therapeutics, drug targets and
industrially interesting enzymes. Traditionally, such functional genomics studies have required
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the subcloning of cDNA into expression plasmid vectors, a process which can be tedious and
time-intensive. This process can be streamlined by amplifying genes from genomic DNA or
mRNA, and directly introducing them into E. coli CFPS. A pioneering study utilized this
method to express 52 gene targets in parallel in CFPS, supplemented with a cocktail of cofactors
and metal ions to yield adequate amounts of products for calorimetric assays without purification
(Woodrow et al. 2006). The supplemental cocktail often increased the activity of enzymes at the
expense of their solubility, suggesting the need for further optimizations. Overall, the method
bypassed time-consuming tasks such as cloning and protein purification, paving the way for
rapid, high-throughput protein screening.
Since then, LET-based CFPS has been used in a variety of different functional genomics
studies. In particular, LET-based wheat-germ CFPS has been explored as a promising tool for
malarial vaccine development (Arumugam et al. 2014; Richards et al. 2013). Malaria, caused by
the protozoans of the Plasmodium genus which are transmitted by mosquito vectors, has seen a
recent resurgence due to rising multidrug- and insecticide-resistance. A malarial vaccine would
dramatically augment current strategies to combat the disease, which rely mainly on drugs and
insecticides. However, vaccine discovery is hampered by a complex life cycle, high antigenic
diversity, immune evasion and difficult functional expression of antigens in vivo, necessitating
an expression method which can rapidly produce large varieties of eukaryotic proteins. The
wheat-germ CFPS system can fulfill this role compellingly, as it can be fashioned to quickly
produce small amounts of proteins from an LET-based cDNA library created via PCR techniques
(Arumugam et al. 2014; Tsuboi et al. 2008). The resulting products could be functionally
assessed or immunoscreened to identify promising candidates for subsequent screenings. LETbased wheat-germ CFPS was able to express 478 of 567 genes from the P. falciparum genome,
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demonstrating its potential for malarial vaccine discovery (Tsuboi et al. 2010). This method,
along with other CFPS systems, was employed to express 46 malarial antigens for a longitudinal
cohort study which provided critical insights into natural human immunization against malaria,
and identified new vaccine and biomarker candidates (Shrestha et al. 2014).
In another study, LET-based CFPS was used to engineer a bacterial “endoplasmic
reticulum” prototype by identifying chaperones effective for immunoglobulin folding in
prokaryote systems. A bacterial “endoplasmic reticulum” could enable the rapid antibody
production in prokaryotic systems while maintaining the eukaryotic ability to perform complex
folding and post-translational modifications. Towards this goal, LET-based CFPS was used to
express and screen 20 different candidate chaperones. The study was able to identify two
chaperones which improved trastuzumab folding and assembly 10 to 100 fold, and shed light on
protein-chaperone interactions for immunoglobulins (Groff et al. 2014). Future studies could
continue to identify enzymes needed to mimic natural folding and modification pathways during
industrial antibody production.
The LET-based CFPS method could also be applied towards investigating the functions
of unknown proteins for applications in biocatalyst discovery and development. Recent advances
in computational tools, such as sequence searching of metagenomes and databases, can
accelerate transaminase discovery, but need to be accompanied by adaptable methods of
experimental confirmation. A proof-of-concept study used LET-based CFPS to identify new
transaminases, which are used to produce chiral amines, an important type of intermediate
compound in many pharmaceuticals syntheses (Tufvesson et al. 2011; Yang and Ding 2014). In
the experiment, 9 putative transaminases were expressed in LET-based CFPS along with 2
known transaminases as controls, and screened against 16 potential substrates in a colorimetry
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assay (Kwon et al. 2010). Notably, PCR products were amplified directly from bacterial
colonies, shortening the entire workflow into hours. In the future, LET-based CFPS could be
developed into a powerful experimental companion to computational approaches, especially if it
can be utilized to screen more detailed parameters, such as biocatalyst substrate specificity,
enantioselectivity and reaction equilibrium.

5.3.2

Protein Microarrays
Protein microarrays are a powerful assaying method that can simultaneously screen many

proteins’ activity and interactions, with potential impacts in functional proteomics studies,
medical diagnostics, biomarker discovery (Matarraz et al. 2011) and personalized medicine (Yu
et al. 2010). Despite this, protein microarrays have yet to replicate the success of DNA
microarrays due to several persisting technical challenges – proteins are often time-consuming to
express, purify and capture onto surfaces, and they can be difficult to store long-term without
degradation. LET-based CFPS offers an attractive solution to these problems, as it enables in situ
protein synthesis and direct surface attachment in a streamlined and just-in-time manner,
eliminating the need for protein storage(He et al. 2008b).
Several methods exist for creating protein microarrays using LET-based CFPS. In the
protein in situ array (PISA) method, LETs are supplied in solution with the CFPS extract, which
is applied directly onto the chip, either by droplet or microfluidics (Seefeld et al. 2012). The
protein products are expressed in situ and in parallel, then captured by preexisting purification
tags. The PISA method has been demonstrated notably with antibody fragments, and in
miniaturized formats (40 nL) (Angenendt et al. 2006; He et al. 2008b; He and Taussig 2003).
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In the DNA array to protein array (DAPA) method, protein microarrays are “printed”
from DNA arrays (He et al. 2008a; Stoevesandt et al. 2011). In this method, a DNA array chip is
placed face-to-face onto a Ni-NTA-coated chip. CFPS extract is applied at the interface between
the two chips, where polyhistadine-tagged protein products are captured on the Ni-NTA surface,
forming in situ a protein array with well-defined and reproducible spot profiles. The DNA array
is then removed and can be reused for subsequent protein microarray production.
Protein microarrays produced by LET-based CFPS have already been utilized in enzyme
screening (Chandrasekaran and Singh 2014), protein-protein interaction studies (Casado-Vela et
al. 2014; He and Taussig 2007; Nand et al. 2014), and biosensors (Seefeld et al. 2012). The
unique synergy of LET-based CFPS and protein microarrays has become a highly active area of
study, with numerous reviews dedicated to the subject (Berrade et al. 2011; He 2008; Kilb et al.
2014; Timm and Niemeyer 2013).

5.3.3

Difficult-to-Express Proteins
Not bound by the limits of the cell, LET-based CFPS can express proteins which are

difficult to produce in vivo – many of which are therapeutically relevant. For example, onconase,
a toxic ribonuclease derived from the oocytes of the Northern Leopard Frog, is a potential
cancer therapeutic (Ardelt et al. 2008; Fiorini et al. 2015; Smolewski et al. 2014). However,
oocyte culture and harvest procedures, as well as recombinant recombinant expression methods,
involve extremely labor-intensive purification or refolding steps. Recently, active and soluble
onconase was successfully expressed in CFPS at 1.8 mg/mL by continuously supplementing the
reaction with tRNAs at optimized intervals to counter the ribonuclease activity of nascent
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onconase products (Salehi et al. 2015). This illustrates that LET-based CFPS can be highly
customized to efficiently produce proteins that are otherwise difficult to express.
As another example, membrane proteins, including successful drug targets such as Gprotein coupled receptors (GPCR), are notoriously difficult to express in vivo at high titers
because of their high hydrophobicity. Cell-free systems can tolerate cytotoxic expression levels
of membrane proteins, all the while being open to the addition of detergents or nanodiscs to
stabilize nascent membrane proteins (Orbán et al. 2015), and have demonstrated efficient
expression of membrane proteins (Henrich et al. 2015; Katzen et al. 2009), including GPCR
(Kaiser et al. 2008; Orbán et al. 2015). Near plasmid-level yields of GPCR have been reported
using LET in both crude extract and PURE systems (Haberstock et al. 2012; Kuruma and Ueda
2015). This enables LET-based CFPS to be an effective platform for expressing and studying
membrane proteins.
For example, LET-based CFPS can address problems in NMR studies of membrane
proteins, which are often challenging due to broad resonance lines that lead to congested spectra
where residue assignment is difficult. Various site- and residue-specific labeling techniques are
simple but powerful ways to overcome this problem. CFPS systems allow for rapid expression of
the isotopically labeled proteins for direct spectroscopic analysis without chromatographic
purification (Kigawa et al. 1999; Yokoyama 2003). In addition, CFPS systems’ lack of metabolic
conversion between amino acids enables amino acid-selective isotope labeling of proteins
(Kigawa et al. 1995). The small reaction volume of cell-free systems means that expensive
isotope-labeled amino acids are used sparingly (Ozawa et al. 2006). Most important, single-site
amino acid labeling requires rapid, parallel protein expression, which lends itself naturally to
LET-driven CFPS (Haberstock et al. 2012; Ozawa and Qi 2014; Wu et al. 2007). In one notable
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study, an NMR spectrum of dengue virus protease complex was obtained in less than 24 hours –
which included PCR production of LETs, 7-hour CFPS, and an overnight dialysis (Wu et al.
2007). The protein complex of choice would have been difficult to produce in vivo due to its high
rate of degradation, but was readily obtained using CFPS, highlighting the robustness of cell-free
systems. Sixteen valine residues were systematically targeted via site-specific, parallel mutation
into 15N/13C-labeled isoleucine. The accelerated production of these labeled variants was made
possible by the LET-based CFPS platforms in the experiment. As only isoleucine was isotopelabeled, the missing peaks from the HSQC spectrum of a mutant protein led to residue
identification in the wild-type protein.
Only a small number of GPCR are currently targeted by marketed drugs, while a
significant number of all human GPCR elucidated by the Human Genome Project are
“orphaned”. These facts suggest that this field represents a fertile application space for LETCFPS in the future.

5.3.4

Optimizing Complex Systems
LET-based CFPS enables rapid iterations of screenings to optimize complex engineered

biological systems across multiple variables. For example, protein-based biologics have
complicated and diverse physicochemical properties and stability characteristics that need to be
accommodated during production. In particular, soluble antibody expression and assembly
depends on successful disulfide bond formation and the proper interaction between chaperones,
light chains and heavy chains at favorable ratios. Therefore, in vitro production of antibodies
needs to optimize (1) the redox conditions for disulfide bond formation, and (2) the relative
expression levels of light and heavy chains (Feige and Buchner 2014; Lee et al. 1999; Simmons
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et al. 2002). The relative expression levels of the two chains can be coordinated by fine-tuning
the interaction between the ribosomal S1 protein and 5’ UTR RNA via sequence mutations in the
translation initiation region (TIR). This interaction is not yet well understood, necessitating
combinatorial screening of a library of TIR with single point mutations. LET-based CFPS was
employed to screen a library of LETs with varying TIR, and optimize the antibody fragment
production across multiple glutathione buffers (Yin et al. 2012). Highly functional antibody
fragments such as single-chain variable fragments have been synthesized in LET-based CFPS
(Han et al. 2006; Stech et al. 2014). Recently, the synthesis of a fully assembled, full-length
antibody, trastuzumab has also been realized in CFPS (Yin et al. 2012), suggesting that the future
horizon of LET-based CFPS could extend to the rapid synthesis and screening of whole
antibodies.
Another application for LET-based CFPS is synthetic biological circuits, where
standardized regulatory elements are assembled in modular fashion to give rise to logic gate-like
behavior. Currently, synthetic biological circuits are often prototyped through time-consuming
reiterations between in silico design and revision and in vivo assembly and testing.
Consequently, the design and assembly of sophisticated large-scale circuits can demand an
enormous number of man-hours, necessitating a more rapid expression system for shorter testing
cycles. LET-based CFPS is an ideal candidate for this role, as it allows for circuit assembly and
testing in a well-characterized, sufficient approximation of the in vivo environment of E. coli,
while bypassing time-intensive cloning and propagation steps. A proof-of-concept study
demonstrated this potential by comparing genetic switch behavior across LET and plasmid-based
circuits using 12 commonly used promoters (Sun et al. 2013). The study found that LET- and
plasmid-based circuits were comparable to in vivo at most concentrations. Future studies could
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carry out comparable experiments with more complex circuits – such as oscillators, logic gates,
translational regulators and chaotic systems, which already have been constructed in CFPS – and
thus be able to program more complex and intricate computing behavior (Hockenberry and
Jewett 2012; Hodgman and Jewett 2012; Siegal-Gaskins et al. 2014).

5.3.5

Conclusion
Proteins carry significant scientific and practical interest as potential therapeutic

biologics, drug targets and biocatalysts. Due to the complex nature of proteins, there is a growing
need to make and evaluate proteins in a simple and timely fashion. LET-based CFPS provides an
open and versatile platform for rapid and parallel protein synthesis. LET-based CFPS has been
applied in functional and structural studies, in situ protein microarray production, highthroughput screening and pre-production bioprocess optimization. These achievements strongly
suggest that the unique advantages of LET-based CFPS will play a spearheading role in novel
biologics discovery, future personalized medicine, and other protein-related fields.
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Figure 5-2: Gu-HCl inhibits Protein Expression Activity in CFPS.
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6

INCORPORATION OF AN UNNATURAL AMINO ACID INTO THE HUMAN
BETA 1 ADRENERGIC RECEPTOR

Chapters 6 and 7 are resulted from a collaboration with Dr. Frank Bernhard and Ralf
Rues at the Goethe University of Frankfurt. The project was partially funded by the Cancer
Research Fellowship of the Simmons Center for Cancer Research. Undergraduate student
Gregory Nielsen at the Bundy Biotechnology Lab also contributed to the work.
Due to the large number of abbreviations used in this chapter, a list of relevant
abbreviations are provided here: AcP – acetyl phosphate; CECF – continuous exchange cellfree; CFPS – cell-free protein synthesis; CoA – coenzyme A; GPCR – G-protein coupled
receptor; IVT-tRNA – in vitro transcribed tRNA; NAD - nicotinamide adenine dinucleotide;
pAz – p-azidophenylalanine; PEP – phosphoenol pyruvate; pPa – p-propargyloxyphenylalanine;
β1AR – beta 1 adrenergic receptor.

Introduction
G-protein coupled receptors (GPCR) are a class of membrane protein receptors which are
crucially involved in signal transduction and transmembrane transport. Due to their physiological
importance, GPCR are prominent drug targets (Filmore 2004), and an increased understanding of
their structure and dynamics is expected to improve drug development and drug targets
identification (Peng 2009; Sachs and Engelman 2006). In particular, uAA could greatly benefit
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the study of GPCR to generate high quality information at the single-molecular scale by serving
as spectroscopic probes, bioconjugatable moieties, fluorescence, or mimicry of post-translational
modifications (Tian et al. 2017). Unfortunately, with a few exceptions (Daggett and Sakmar
2011; Grunbeck et al. 2011; Ye et al. 2010), the potential impact remains largely unrealized due
to GPCR being difficult to express functionally. Conventional in vivo expression of GPCR are
complicated by cytotoxicity, insufficient membrane space, and inefficient folding and transport.
These challenges often need to be overcome by trial-and-error selection of optimal host and finetuning of expression parameters (Bill et al. 2011) – a time and labor-intensive process.

Figure 6-1: Incorporating uAA into GPCR using a customized CFPS system.
(1) Basic components of a cell free system includes DNA, cell extract and cofactors. Cell extract contains
vital expression machineries such as tRNA and ribosomes. (2) Supplementary components, such as
nanodiscs and UAA-incorporating elements, can be directly added and optimized, yielding a (3) highly
customized cell free system. This figure shows a nascent membrane protein (blue) expressed with UAA
(red) incorporation and in situ stabilization via nanodiscs (green). (4) The desired product, which is UAAincorporated membrane protein stabilized in nanodiscs. The incorporated UAA can be utilized as unique
probes in structural and dynamics studies.

This chapter explores CFPS as a compelling platform to overcome the above-mentioned
difficulties surrounding GPCR expression. Due to the lack of a cell and its membrane, CFPS
systems can tolerate cytotoxic levels of membrane protein expression, and allow for direct
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addition and optimization of supplemental components. Therefore, we explore uAA
incorporation in GPCR in a CFPS system which has been modified by the addition of lipid
molecules to solubilize and stabilize the GPCR, and heterologous translational machineries for
uAA incorporation (Figure 6-1).

Methods

6.2.1

DNA Preparation
A modified construct of human β1AR in a pET21a vector was used, as previously

described (Rues 2016). The construct included thermo-stabilizing mutations (K85A, M107V,
Y244A, A316L, F361A, F372M; Δ1-46, 261-306, and 392-477) and sequences for sfGFP and
six histidines at the C-terminus. The thermo-stabilized construct was mutated to include amber
stop codon at Y210 and F218 respectively using QuikChange Mutagenesis (Agilent
Technologies, Santa Clara, CA), following manufacturer instructions. Primer sequences for the
Y210TAG mutation were as follows: forward – GCGCCGCTGCTAGAACGATCCGAAATGC,
reverse – GCATTTCGGATCGTTCTAGCAGCGGCGC. Primer sequences for the F218TAG
mutation were as follows: forward – CCGAAATGCTGCGATTAGGTGACCAACCGC, reverse
– GCGGTTGGTCACCTAATCGCAGCATTTCGG).

6.2.2

Detergent and Nanodisc Preparation
A stock of Brij78 was prepared at 5% (w/v). Nanodiscs (ND) were prepared as described

previously (Roos et al. 2014). Briefly, the membrane scaffolding protein (MSP) MSP1E3D1 was
expressed and purified using his column affinity chromatography. The purified MSP was
combined with lipid 1,2-dioleoyl-sn-glycero-3-phospho-(1’-rac-glycerol) at a 1:85 ratio, along
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with detergent dodecylphosphocholine (0.1% w/v), to a final volume of 10 mL. Lipid
concentrations were adjusted to an 85:1 ratio in relations to MSP concentrations. Detergent
concentration was 0.1% w/v. The mixture was incubated over 1 hour to fully dissolve the lipid
by detergent. The assembly of the nanodisc complex was induced by gradual dialysis against a
large volume of buffer (10 mM Tris, 100 mM NaCl) at room temperature over 72 hours, with
buffers refreshed at least 3 times. The assembled nanodiscs were clarified via centrifugation and
concentrated via ultrafiltration, and stored in -80 °C until usage(Roos 2012).

6.2.3

Cell-Free Protein Synthesis
Cell-free extract preparation and cell-free reactions were performed as described

previously (Shrestha et al. 2014; Wu et al. 2015) with Escherichia coli BL21 (DE3) StarTM
(Invitrogen, Carlsbad, CA) harboring the plasmid pEVOL-pPrF, which encodes for the mutated
Methanocaldococcus jannaschii aminoacyl-tRNA synthetase/tRNA pair (Chin et al. 2002). Cellfree reactions were run in continuous exchange format, as described previously (Schneider et al.
2010; Schwarz et al. 2007). In this setup, the reaction mixture (50-100 μL) is separated from the
feed mixture (950 μL) by a dialysis membrane (MWCO: 12-14 kDa, Sigma Aldrich). The
reaction was modified with supplemental detergents or nanodiscs. Product quantification was
done by fluorescent measurement of the β1AR’s GFP tag using a TECAN Genius Pro
fluorescence reader (Tecan, Männedorf/Zürich, Switzerland), as described previously (Schwarz
et al. 2010).

6.2.4

Radioactive Ligand Binding Assay
Measurements of ligand binding and binding kinetics have been previously described

(Rues 2016). Briefly, receptor binding activity was measured by varying receptor concentrations
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at a fixed concentration of radioactively labeled ligand. Thus, receptor samples were diluted to
concentrations ranging between 1 to 30 ng/μL at 30 μL, and incubated with 50 nM H3-labeled
alprenolol ([3H]dihydroalprenolol; 3H-DHA) (Biotrend, Cologne, Germany). The binding
reaction was buffered 50 mM HEPES, pH 7.5, 1 mM CaCl2, 5 mM MgCl2, 0.2% [w/v] BSA.
Unspecific binding was determined by incubating the sample products in an excess of unlabeled
ligands (40 μM) prior to adding labeled alprenolol. Unbound ligand was removed via filtration
using pretreated GF/B glass fiber filter (Millipore, Eschborn, Germany). Bound ligands were
quantified via scintillation counting using Hidex 300 SL Liquid Scintillation Counter (Hidex,
Turku, Finland).
Binding kinetics were characterized by varying radioactively labeled ligand
concentrations from 0.1 to 500 nM at a fixed concentration of sample receptors (50 nM). Binding
reaction conditions and characterization of unspecific binding were carried out like in binding
activity measurements, as described above.

Results & Discussion

6.3.1

Background
GPCR detect specific molecules outside the cell and activate internal signal transduction

pathways, which ultimately leads to cellular responses. Many of these cellular responses control
critical physiological functions, such as immune system regulation, homeostasis maintenance,
and cardiovascular behavior. GPCR activation is a complex, multi-step process that includes
ligand recognition, binding, and conformational change. Understanding of GPCR structure and
dynamics can improve targeted drugs and minimize side-effects. Several existing methods to
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investigate GPCR benefit from uAA as a single, targetable moiety with useful functional groups
– e.g. nuclear magnetic resonance spectroscopy (Sobhanifar et al. 2010), Förster resonance
energy transfer (Halder et al. 2015), and Fourier transform infrared spectroscopy (Ye et al.
2010).
This work focused on incorporating uAA into human beta1 adrenergic receptor (β1AR), a
ligand-binding GPCR which has not been characterized as well as photoreceptors such as
rhodopsin. We used a β1AR construct with thermostabilizing mutations (Serrano-Vega et al.
2008; Serrano-Vega and Tate 2009) and GFP-tag at the C-terminus. In particular, we
investigated the second extra-cellular loop (ECL2) of β1AR, which acts as a “lid” above the
binding cavity formed by the transmembrane regions. During a ligand-induced conformational
change, the ECL2 “closes the lid” and helps stabilize the ligand in the binding pocket (Wheatley
et al. 2012). Y210 and F218 were selected as incorporation sites in ECL2 due to their structural
similarities to tyrosine-analogs p-propargyloxyphenylalanine (pPa) and p-azidophenylalanine
(pAz) (Figure 6-2).

6.3.2

Optimization of GPCR Expression in CFPS
Several GPCR have been previously expressed in cell-free systems modified with lipid

additives (Proverbio et al. 2013; Rues 2016). Such systems could be further modified with
heterologous translational machineries for uAA incorporation. A major challenge in such a
system would be to obtain adequate product yields despite imperfect uAA incorporation
efficiencies. We considered a baseline expression rate of 0.5 mg/mL β1AR to be adequate for
uAA incorporation, downstream purification and assaying. An important factor in obtaining such
yields is ATP generation for efficient aminoacylation and polypetide synthesis. Thus, we
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optimized cell-free energetics for β1AR expression. During the optimization process, all cell-free
reactions were run in the presence of Brij78, a mild detergent which solubilize GPCR products
cost-efficiently but do not promote their functional folding.

Figure 6-2: Incorporation of uAA into human beta-1 adrenergic receptor.
(A) Since human b1AR has not been structurally characterized, it is represented by the turkey b1AR with
which it has a high degree of homology. It is 76% identical with the human counterpart. (B) The
analogous Y210 and F218, in external cellular loop 2, correspond to Y193 and F201 of turkey
(2VT4.PDB). (C) Alprenolol, a non-selective antagonist of b1AR, was used as ligand for this study.

A widely used cell-free energy system is PANOx, which uses phosphoenol pyruvate
(PEP) as its main energy molecule, along with supplementary cofactors such as nicotinamide
adenine dinucleotide (NAD) and coenzyme A (CoA) (Calhoun and Swartz 2007; Kim and
Swartz 2001). However, the batch-format PANOx system failed to produce adequate amounts of
GPCR (Figure 6-3A; unfilled circles ○ #1,2). Such yields were increased four-fold by adopting a
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continuous-exchange cell-free (CECF) format, where energy sources can be supplied and
inhibitory levels of inorganic phosphates can be diluted via passive transport through a
membrane (Figure 6-3A; filled circle ● #3).
An energy system alternative to PANOx utilizes acetyl phosphate (AcP) as a another
energy source in addition to PEP, along with pyruvate kinase and acetyl kinase for ATP
regeneration (Schwarz et al. 2007). Other differences include the absence of NAD and CoA, as
well as different cofactor and salt concentrations, as further detailed in Section 7.2.

Figure 6-3: An economic analysis of β1AR expression in CFPS.
(A) Batch-format CFPS (unfilled) failed to produce adequate amounts of β1AR. The continuous exchange
format (filled) produced >0.2 mg/mL of both β1AR (red) and β1AR-pPa (green), albeit at higher cost.
The PEP-AcP energy system supplemented by NAD (♦) was most cost-efficient, compared PEP-AcP (▲)
and PANOx (●) systems. For β1AR F218pPa, the addition of NAD or IVT-tRNA improved yields at
lower cost (#8, 9). (B) A cost distribution analysis of the hybrid PEP-AcP system – with supplementation
of NAD and nanodiscs – show that it uses cell-free extract and plasmid DNA efficiently compared to the
batch system (Shrestha et al. 2014).

To better take advantage of the CECF format, we used purified pyruvate kinase for
enzymatic renewal of PEP. It also utilizes Acetyl phosphate and utilizes the acetyl kinase,
present in E. coli extract, to renew AcP. The system also uses slightly different cofactors and salt
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concentrations, as outlined in Chapter 7. The PEP-AcP system significantly increased yields to
around 1 mg/mL (Figure 6-3A; filled triangles ▲ #5, 6).
Lastly, we explored a hybrid of the two energy systems by supplementing the PEP-AcP
system with NAD and CoA. These molecules have not been explored in a CECF cell-free
system. The addition of NAD increased expression yields by 30% while maintaining comparable
cost efficiency (Figure 6-3A; filled diamond ♦ #7). We found that CoA did not help the system
(not shown). Overall, adequate yields of β1AR could be obtained by adopting the CECF format
and adjusting the system’s energetics. A hybrid energetics system of PEP-AcP and NAD
supplementation resulted in highest yields (Figure 6-3A; filled diamond ♦ #7), and efficiently
used cell-free extract and plasmid DNA (Figure 6-3B).

6.3.3

Incorporation of uAA into GPCR in Cell-Free System
Using the above-described format, we studied the incorporation of two tyrosine-analog

uAA – pPa and pAz – into β1AR. The two uAA have function groups of alkyne and azide
respectively, to which various spectroscopic probes could be conjugated via Copper(I)-Catalyzed
Alkyne-Azide Cycloaddition click chemistry (Bundy and Swartz 2010a). In addition, pAz offers
a unique infrared spectroscopic signature useful in Fourier transform infra-red spectroscopy (Ye
et al. 2010). These functionalities could be used to study GPCR structure, dynamics, and
regulation by post-translational modification or oligomerization (Tian et al. 2017). The necessary
heterologous tRNA and aminoacyl-tRNA Synthetase for uAA incorporation were pre-expressed
in the cell-extract during culturing and preparation; the appropriate uAA – either pPa or pAz –
was added to both the chambers of the CECF system during reaction assembly.
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Incorporation rates of pPa and pAz into β1AR at Y210 and F218 were comparable at
around 0.2 mg/mL (Figure 6-4; data bars #2, 5). Successful incorporation was confirmed by the
lack of products when no uAA was provided to the reaction (Figure 6-4; grey data bar #8). A
previous study explored the addition of in vitro-transcribed tRNA (IVT-tRNA) to significantly
increase CFPS yield when tRNA are rate-limiting reagent (Salehi et al. 2016). Since uAA
incorporation can be limited by tRNA concentrations as well (Figure 9-6), IVT-tRNA addition
was explored to increase uAA-GPCR yields. Similarly, we also explored the addition of NAD,
which can facilitate ATP regeneration used in aminoacylation. The addition of IVT-tRNA and
NAD did not affect β1AR Y210pPa yield, but increased β1AR F218pPa yield (Figure 6-4;
yellow data bars #3, 6) at comparable cost efficiency (Figure 6-3; filled diamond ♦ #8 and
triangle ▲ #9). This observation, as described previously in a similar system (Albayrak and
Swartz 2013), suggests that the heterologous tRNA are not always the limiting factor in the
dynamic and complex process of uAA incorporation. Potential explanations for this variation
include C-terminal amino acid effects on ribosomal termination efficiency (Pierson et al. 2016),
or “the fourth base of the stop codon” effects on release factor-stop codon interaction (Schinn et
al. 2017).
Once adequate expression of β1AR was demonstrated, their activities were quantified.
Active GPCR folding requires an appropriate lipid environment, which lipid-protein complexes
called nanodiscs. Ideal lipid compositions of nanodiscs need to be screened in a combinatorial
manner; nanodisc compositions for β1AR were characterized by our collaborators at the Dötsch
Lab, and has been thoroughly described elsewhere (Rues 2016).
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Figure 6-4: Yields of uAA-β1AR in CFPS.
A modified, continuous-exchange CFPS allows for incorporation of pPa at Y210 and F218 at 0.2 mg/mL
(light green; data bars #2, 5). Incorporation yields for pAz were comparable (yellow; data bars #3, 6).
Addition of purified heterologous tRNA further increased yields at F218 (dark green; data bar #7), but did
not affect site Y210 (dark green; data bar #4). Lack of either uAA resulted in negligible yield (grey; data
bar #8)

The binding activity of pPa-incorporated β1AR to the non-specific antagonist alprenolol
were evaluated in above-described CECF reactions, in the presence of purified nanodiscs. The
β1AR-Y210pPa mutant, whose incorporation site neighbors ligand-binding interactions but is
itself not directly involved in ligand binding, conserved approximately 50% activity (Figure 65A). Binding kinetics of β1AR-Y210pPa were similar to that of β1AR, although the ligand-
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receptor interaction was seven-fold weaker, as represented by the disassociation constant Kd
(Figure 6-5BC). The preservation of significant activity and binding mechanism suggests that
β1AR-Y210pPa could potentially be used to study β1AR ligand binding.

Figure 6-5: Activities of uAA-β1AR in CFPS.
(A) The activities of β1AR constructs are described. β1AR-Y210pPa conserved about 50% of nonmutated β1AR activity, while β1AR-F218pPa lost all activity. (B) The human β1AR binding activity can
be described using a Michaelis-Menten model with a comparable Kd = 5.376. (C) The Y210pPa variant
exhibited similar mechanistic behavior, albeit with a higher Kd = 34.80.

The β1AR F218pPa mutant lost all activity, which is likely due to the incorporation site’s
direct involvement in the ligand binding process. Human β1AR F218 corresponds to turkey
β1AR F201, which forms a weak hydrogen bond with ligands’ cyano-moiety (Warne et al.
2008b). This suggests that uAA can seriously disrupt residue-ligand interactions, even when the
uAA structurally similar to the substituted natural residue. The partial and total losses of activity
in β1AR mutants highlight uAA location as an important design factor in engineering uAAGPCR.
The results above point to multiple design considerations in engineering GPCR with
uAA, such as including uAA location, reaction compositions, and lipid environment. Such
factors are difficult to predict, and likely require series of screening. Here, we have described a
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CFPS workflow which evaluates these factors reiteratively in detergent- and nanodisc-based
reactions (Figure 4-6), faster compared to conventional mammalian cell-based methods. Such an
approach could especially benefit the growing number of ‘orphaned’ GPCR.

Figure 6-6: A CFPS-based reiterative screening of GPCR.
A reiterative CFPS-based workflow could be employed to quickly optimize reaction conditions, uAA
location and nanodisc lipid composition.

Conclusion and Future Works
CFPS is a promising platform to incorporate uAA into functional β1AR at assayable
amounts (>0.2 mg/mL). Such CFPS system should be fashioned in continuous-exchange format,
and contain appropriate lipid additives and heterologous translational machineries. This CPFSbased method can rapidly screen key factors of GPCR engineering using uAA.
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Future works could confirm and expand on these benefits of the presented approach.
Specifically, the characterization of other uAA could shed more light on uAA effect on yield and
activity. Particular locations of interest include the transmembrane region 6, and N- and Ctermini (Dalton et al. 2015; Kobilka 2007). Such incorporated uAA should be used to
demonstrate their usefulness in concrete applications. Lastly, other GPCR could be tested to
confirm the method’s generality. For example, the endothelin 1 receptors, which are implicated
in various cancers and have been characterized in CFPS expression previously (Proverbio et al.
2013), could be a compelling future target.
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7

SUPPLEMENTARY MATERIAL TO CHAPTER 6

Sequence of Thermo-stabilized Human Beta 1 Adrenergic Receptor
Target residues for amber stop codon (TAG) substitution is boxed and marked in green.
Surrounding primer sequences are colored in yellow.

Nucleotide Sequence
agcccggaaccgctgagccagcagtggaccgcgggcatgggcctgctgatggcgctgattgtgctgctga
ttgtggcgggcaacgtgctggtgattgtggcgattgcgagcaccccgcgcctgcagaccctgaccaacct
gtttattatgagcctggcgagcgcggatctggtggtgggcctgctggtggtgccgtttggcgcgaccatt
gtggtgtggggccgctgggaatatggcagctttttttgcgaactgtggaccagcgtggatgtgctgtgcg
tgaccgcgagcgtgtggaccctgtgcgtgattgcgctggatcgctatctggcgattaccagcccgtttcg
ctatcagagcctgctgacccgcgcgcgcgcgcgcggcctggtgtgcaccgtgtgggcgattagcgcgctg
gtgagctttctgccgattctgatgcattggtggcgcgcggaaagcgatgaagcgcgccgctgctataacg
atccgaaatgctgcgattttgtgaccaaccgcgcgtatgcgattgcgagcagcgtggtgagcttttatgt
gccgctgtgcattatggcgtttgtggcgctgcgcgtgtttcgcgaagcgcagaaacaggtgaaaaaaatt
gatagcgcgggcaaacgccgcccgagccgcctggtgctgctgcgcgaacagaaagcgctgaaaaccctgg
gcattattatgggcgtgtttaccctgtgctggctgccgttttttctggcgaacgtggtgaaagcgtttca
tcgcgaactggtgccggatcgcctgtttgtggcgtttaactggctgggctatgcgaacagcgcgatgaac
ccgattattctgtgccgcagcccggattttcgcaaagcgtttcagggcctgctggcggcg

Amino Acid Sequence
SPEPLSQQWTAGMGLLMALIVLLIVAGNVLVIVAIASTPRLQTLTNLFIMSLASADLVVGLLVV
PFGATIVVWGRWEYGSFFCELWTSVDVLCVTASVWTLCVIALDRYLAITSPFRYQSLLTRARAR
GLVCTVWAISALVSFLPILMHWWRAESDEARRCYNDPKCCDFVTNRAYAIASSVVSFYVPLCIM
AFVALRVFREAQKQVKKIDSAGKRRPSRLVLLREQKALKTLGIIMGVFTLCWLPFFLANVVKAF
HRELVPDRLFVAFNWLGYANSAMNPIILCRSPDFRKAFQGLLAA
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Comparison of Cell-Free Energy Systems
Table 7-1: Comparison of PANOx and PEP-AcP Energy Systems.

Stabilizing
Agents

Compound

PANOx
System

PEP-AcP
System

Putrescine

1

0

Spermidine

1.5

0

PEG

0

2%

DTT

0

2

cOmplete

0

1x

RNAsin

0

0.3 U

Amino Acids Amino Acids

0.5 mM of premix

NTP

1x

Energy
Sources

Salts

Coenzymes
& Cofactors

ATP, CTP, GTP, UTP
Acetyl Phosphate

0

20

Phenolpyruvate
Phosphate

33.33

20

NH4(GLU)•H2O

10

Mg(GLU)2•4H2O

variable

0

Mg(Oac)2

0

variable

K(GLU)•H2O

175

0

K(Oxalate)•H2O

2.7

0

KOAc

0

130

HEPES/EDTA

0

0.1

Pyruvate Kinase

0

0.04 mg/mL

NAD

0.33

0

Coenzyme A

0.27

0

tRNA

0

0.5 mg/mL

Folinic Acid

0.17 mg/mL

0.1 mg/mL

Final Concentrations are in units of mM, unless otherwise stated.
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EFFICIENT TRNA DEGRADATION AND QUANTIFICATION IN
ESCHERICHIA COLI CELL EXTRACT

Chapters 8 and 9 are adapted from a publication titled “Efficient tRNA Degradation and
Quantification in Escherichia Coli Cell Extract Using RNase-Coated Magnetic Beads: A Key
Step Towards Codon Emancipation” (Salehi et al. 2017), which was led by former colleagues in
the Bundy Biotechnology Lab, Dr. Mark Smith and Dr. Amin Salehi. I contributed significantly
to the associated writing and experimental work, with particular emphasis on minimal codon set
design, as well as design and production of peptide constructs.

Introduction
A minimized genetic code promises to expand the available proteomic toolset with
implications in many fields, including biotherapeutics (Cho et al. 2011; Smith et al. 2013),
biocatalysis (Wu et al. 2015), protein labeling (Lang and Chin 2014), and minimal cells (Lajoie
et al. 2013). Such a rewriting of the genetic code requires the decoupling and reengineering of
the codon-tRNA-amino acid relationships, which defines the genetic coding of proteins by
nucleic acids (Crick et al. 1961). These relationships, while extremely functional and adaptive,
are also redundant and complex (Budisa 2004; Wang and Schultz 2005). In theory, the great
redundancy of codon-tRNA-amino acid relations has the potential to be exploited for
incorporation of unnatural amino acids. Indeed, promising efforts have expanded the genetic
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code using stop codons or 4-base codons (Neumann et al. 2010; Wang et al. 2001).
Unfortunately, these methods are constrained by a limited number of available codons for
emancipation, or by competition by native tRNA and release factors. The emancipation of sense
codons has the potential to free up high numbers of codons for efficient unnatural amino acid
incorporation. However, sense codon reassignment has been met with many challenges such as
low fidelity or poor rates of incorporation (Brocker et al. 2014; Hong et al. 2013; Mukai et al.
2015; Quast et al. 2015). Furthermore, the extensive reassignment of sense codons throughout
the genome would necessitate massive mutagenesis or complete genome replacement to maintain
the production of active endogenous proteins and maintain cell viability. Here we present an
efficient and cost-effective alternative strategy where the codon-tRNA-amino acid relationship is
reengineered in an open and highly customizable in vitro environment.
In vitro or “cell-free” protein synthesis systems provide a compelling platform to
decouple the codon-tRNA-amino acid relationship for multiple reasons: 1) The system utilizes
harvested biological machinery (e.g. ribosomes, elongation factors, tRNA synthetases), thus
genome-wide mutagenesis replacing sense codons is not necessary to maintain the activity of
transcription/translation enzymes. 2) The system is “dead”, allowing for manipulations that
would devastate in vivo systems such as the complete removal or degradation of tRNA. 3) The
system is open, facilitating direct addition of heterologous machinery and exquisite control of
reaction conditions such as pH, osmolarity, and reagent concentration (Des Soye et al. 2015;
Smith et al. 2014c). Based on these features, the genomic code could be minimized and
manipulated by complete or near-complete destruction of the native tRNA followed by
repopulation with a synthetic minimal set of tRNA (Figure 8-1).
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Figure 8-1: An in vitro approach for tRNA depletion and replacement with synthetic tRNA.
The cell extract is treated using RNase A-coated magnetic beads to efficiently degrade endogenous tRNA.
Synthetic tRNA, produced using in vitro transcription, is used to repopulate the cell-free system with only
the desired tRNA.

A recent study illustrated the potential of a cell-free protein synthesis system as a
platform to reengineer the codon-tRNA-amino acid relationship by demonstrating the decoding
of 61 sense codons by synthetic tRNAs at various efficiencies (Cui et al. 2015; Iwane et al.
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2016). The complete emancipation of sense codons, however, was limited due to insufficient
removal of native tRNA by chromatography, at an average of 62% of a specific tRNA removed
(Cui et al. 2015; Iwane et al. 2016). The PURE system, where individually purified
transcription/translation components are combined, also has the potential to emancipate codons,
but the monetary high cost severely limits its utility (Cui et al. 2015; Iwane et al. 2016). Here we
report a new approach for near-complete depletion of tRNA from E. coli cell extracts as a costeffective platform to emancipate sense codons in vitro. Such efficient tRNA depletion is essential
to reduce the competition between the native and synthetic coding elements for high fidelity
codon reassignment. The presented method is compatible with various approaches of synthetic
tRNA production, including in vitro transcription of T7-promoted tRNA, T7-promoted
hammerhead Ribozyme-tRNA, and flexizyme (Cui et al. 2015; Fechter et al. 1998; Goto et al.
2011). Additionally, for the first time we directly measured residual tRNA using quantitative
real-time PCR and report the inaccuracy of assuming tRNA removal based solely on the indirect
method of protein expression levels.

Material and Methods

8.2.1

Cell Extract Preparation and Treatment to Deplete Endogenous tRNA
Cell extract preparation was performed as previously described (Smith et al. 2014b) using

E. coli BL21 Star™ (DE3) strain. To treat the cell extract and remove endogenous tRNA, RNase
A from bovine pancreas (Sigma) was covalently attached to epoxy superparamagnetic beads
(Dynabeads® M-270 Epoxy, Invitrogen) according to the manufacturer protocol. Briefly, the
reaction buffer was prepared containing 0.02M monosodium phosphate, 0.08M disodium
phosphate, 3M ammonium sulfate, and 6mg/ml RNase A. 60 mg of epoxy beads were
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resuspended in 2ml of dimethylformamide (DMF) to a final bead concentration of 4x109 beads
per mL. Beads were washed two times with PBS/Tween 20 (0.5%Vol) buffer and one time with
PBS buffer. Each time beads were separated from the buffer by magnetic force using
DynaMag™- Spin Magnet (Life Technology). After washing the beads, an equivalent volume of
reaction buffer was added to the beads which were then incubated at 37oC for 24h with end-overend shaking. After the reaction, beads were washed extensively with PBS/Tween and PBS, in
order to remove all unattached RNase A, and were stored in PBS buffer. For cell extract
treatment, the extract was first incubated at room temperature with 0.5 mM
phenylmethylsulfonyl fluoride (PMSF) for 5 min to decrease protease activity of the extract
before adding RNase A beads. After PMSF treatment, the cell extract was treated with RNase A
on beads at a final concentration of 17.5 beads per ml extract and incubated at room temperature
with end-over-end shaking. Treated extract was separated by DynaMag™- Spin Magnet and
transferred to a new microcentrifuge tube (Figure 8-2) and stored at -80oC.

Figure 8-2: Schematic diagram of extract treatment to deplete endogenous tRNA.
a) Ribonuclease A is covalently attached to superparamagnetic beads. After washing steps to remove the
unattached enzyme, the beads were added to the PMSF-treated extract. Later the treated extract is
separated from the RNase beads and transferred to a new micro-centrifuge tube. b) Gel electrophoresis of
purified tRNA from the untreated extract, treated extract for 15min, and purified-bulk tRNA as compared
to Oligo Length Standards ladder (Integrated DNA Technologies, Inc., Iowa, US) (left-to-right 60, 70, 80,
90, and 100 base bands shown).
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8.2.2

Total RNA Purification and qPCR
To investigate the tRNA cleavage efficiency, tRNA was first purified from RNase A

treated extract and non-treated extract using Trizol reagent (ThermoFisher Scientific) and
isopropanol in the form of total RNA. Briefly, 1 equivalent volume of Trizol reagent and 0.2
equivalent volumes of chloroform were added to the cell extracts followed by centrifugation at
15000 RCF for 15 min. The top layers containing the RNA were transferred to new
microcentrifuge tubes and RNA was precipitated using 1.45 equivalent volumes of isopropanol
and 0.45 equivalent volumes of 8 M ammonium acetate. The mixtures were incubated at -20oC
for 20 min and centrifuged at 15000 RCF for 15 min. The pellets were washed with 75% ethanol
and centrifuged for 5 min at 15000 RCF. RNA pellets were resupended in RNAse free water.
For qPCR, reverse complementary DNAs were polymerized using ThermoScript™
Reverse Transcriptase (ThermoFisher Scientific) and reverse primers (Table 1) according to the
manufacturer protocol. The products of this step were subjected to real time quantitative PCR
using KAPA SYBR® FAST qPCR Kits (Kapa Biosystems).
Table 8-1: qPCR Primers for tRNA Quantification.

List of primers used for qPCR of various tRNAs to measure residual tRNA level in treated cell extracts
compared to untreated cell extract

8.2.3

In Vitro Transcription of tRNA
To produce synthetic tRNA, forward and reverse complementary Ultramer® DNA

oligonucleotides (Integrated DNA Technology, forward sequences reported in Figure 9-5c) were
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combined and amplified using a PCR technique. In vitro transcription of tRNA was performed
at 37oC for 2 hr with shaking at 150 RPM using the following reaction conditions: 50 mM TrisCl pH 7.5, 30 mM MgCl2, 5 mM DTT, 5.5 mM Spermidine, 2 mM putrescine, 2 mM NTPs, 2
mg/ml Poly(vinylsulfonic acid, sodium salt) (PVSA), 0.1 mg/ml T7 RNA polymerase, and 10
ug/ml DNA template.

8.2.4

Cell-free Protein Synthesis (CFPS)
Cell-free protein synthesis (CFPS) was performed in a PANOxSP system as described in

previous studies (Jewett and Swartz 2004), with the crucial modification of not adding E. coli
tRNA mixture. The reaction contained 33.33 mM phosphoenolpyruvate (PEP; Roche Molecular
Biochemicals), 10 mM Magnesium glutamate, 10 mM Ammonium glutamate, 175 mM
Potassium glutamate, 2.7mM Potassium Oxalate, 1mM Diaminobutane, 1.5 mM Spermidine,
0.33 mM nicotinamide adenine (NAD), 0.27 mM coenzyme A (CoA), 1.2 mM ATP, 0.86 mM
CTP, 0.86 mM GTP, 0.86mM UTP, 0.17 mM Folinic Acid, 2 mM 19 canonical amino acids
(excluding glutamate), and 12 nM DNA. All components were obtained from Sigma Aldrich
(St. Louis, MO), unless explicitly stated otherwise.
pY71sfGFP vector (Bundy and Swartz 2010b), prepared using Qiagen Maxi-Prep kits,
templated the sfGFP cell-free reactions. The sfGFP yield was determined by fluorescence with a
Synergy MX microplate reader (BioTek Instruments, Winooski, VT, USA). The DNA 1
construct shown in Figure 8-6a was synthesized by GenScript. 5 µM radiolabled-C14 valine
(PerkinElmer Inc. ,Waltham, MA) was added to the CFPS reaction and the protein yield was
measured using scintillation counting based on total and washed sample, as previously described
(Wuu and Swartz 2008a).
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Results and Discussion
To emancipate sense codons and reassign them, the following two steps were performed:
1) native tRNA depletion, where codon-tRNA-amino acid relationships are decoupled, 2)
repopulation of the system with a synthetic set of tRNA, where codon-tRNA-amino acid
relationships are reorganized according to a minimal genetic code (Figure 8-1). In this work, we
present a method of near-complete tRNA depletion in cell extracts and directly measured the
residual native tRNA. The treated extract was capable of producing various proteins and peptides
using purified native tRNA or synthetic tRNA.

Figure 8-3: Normalized protein synthesis of sfGFP under various conditions.
Normalized protein synthesis of sfGFP under various conditions, normalized to the 1.4 mg/ml yield of the
control reaction (untreated extract). a) RNase inhibitor addition to the cell-free protein synthesis at
0.8U/μl reaction restores most of the activity to the 15 min RNase A-bead treated extract. b) Cell extract
incubation with PMSF for 5 min before treatment with RNAse A beads restores most of the activity to the
15 min RNase A-bead treated extract. PMSF treated extract does not require RNase inhibitor, which is
approximately 5-fold less costly than using RNase inhibitor. The error bars represent one standard
deviation for n=3.

8.3.1

tRNA Depletion of Cell Extract
Inspired by a previous study where tRNA was degraded with RNase A, RNase A was

assessed for its ability to degrade tRNA from our system (Figure 8-2) (Kunda et al. 2000). To
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optimize RNase exposure for both tRNA depletion and preservation of translation-essential
rRNA, RNase A molecules were covalently immobilized to epoxy-functionalized
superparamagnetic beads. RNase-coated beads enable: 1) control of RNase A concentration by
adjusting bead concentrations, 2) control of treatment time, 3) rapid removal of RNase by
magnetic force, and 4) facile homogenous mixing of RNAse A to achieve uniform treatment of
cell extract. Bead concentration, treatment time, washing and cleaning steps were fine-tuned to
maximize tRNA degradation and rRNA preservation, as discussed below.
RNase A-bead treatment for 15 min with 17.5 µl RNase A-beads per ml cell extract
(3.5x107 beads/ml) was sufficient to inhibit protein synthesis (Figure 8-3a, 1st and 2nd bars).
However, after the RNase-coated beads were removed from the cell-extract and 2 mg/ml bulkpurified tRNA was supplied, less than 10% of its original protein synthesis capability was
retained (Figure 8-3a, 4th bar). The possibility of residual RNase A in the system, which would
degrade translation-essential mRNA, was assessed by adding RNase Inhibitor (New England
BioLabs, MA) to the cell-free system following the removal of the RNase-coated beads. The
result was a greater than 70% recovery of initial protein synthesis capability after adding bulkpurified tRNA (Figure 8-3a, 5th and 3rd bars). Leaching of covalently immobilized RNase A by
latent proteases in the extract was hypothesized and assessed by adding serine-protease inhibitor
phenylmethanesulfonylfluoride (PMSF) to the cell extract prior to treatment with RNase-coated
beads. Adding PMSF (0.5 mM final concentration) 5 minutes prior to RNase had a similar effect
of adding RNase Inhibitor with greater than 70% recovery of initial protein synthesis capability
after adding bulk-purified tRNA (Figure 8-3b). The ability to degrade tRNA while maintaining
rRNA activity is attributed to a partial shielding effect of ribosomal proteins (Suhasini and
Sirdeshmukh 2006), and the partial loss of protein synthesis capability following RNase
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treatment could be attributed to loss of rRNA function due to RNase A cleavage. Indeed, longer
RNase treatments (30 min, 60 min) resulted in the retention of 58% and 20%, respectively, of the
initial protein synthesis capabilities compared to over 70% retention with 15 min of treatment
(Figure 8-4a). However, significant protein synthesis capabilities of ~300 µg/ml were obtained
even with the 60 min treatment.

Figure 8-4: Extent of tRNA-depletion in cell extracts.
Colors from light to dark represent mild, moderate, and strong pretreatment conditions, respectively,
throughout. a) Effect of different treatment severity on cell extract activity. sfGFP was expressed as a
model protein in treated extract with 2 mg/ml bulk-purified tRNA. Cell extracts were treated for 15, 30,
and 60 min for mild, moderate, and strong treatments, respectively. b) Analysis of residual tRNA of
different treated cell extracts with the qPCR technique. Error bars represent one standard deviation for
n=3.

8.3.2

tRNA Depletion Efficiency
The tRNA concentrations were further quantified in both treated and untreated extracts

using a qPCR technique via tRNA-specific primers (Table 1). Quantification results revealed that
at short treatment times (15 min), significant residual tRNA remained (6-32%), even though
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detectable protein synthesis activity had been eliminated (Figure 8-4b, Figure 8-3). Such residual
tRNA represents inadequate decoupling of the codon-tRNA-amino acid relationship, as they can
compete with heterologous synthetic tRNA resulting in incomplete emancipation and
reassignment.
Increasing the treatment time substantially decreased the residual tRNA. For instance, 30
min treatment of cell extract resulted in a drop of 97% or more in tRNA concentrations for all
targeted tRNAs assessed – Ala(GCC), Arg(CGG), Glu(GAA), Ser(TCG), and Val(GTA). A 60
min RNase A treatment resulted in an average of 99.3% of tRNA degraded for all tRNA
assessed, with greater than 99.5% degradation for Ala(GCC), Arg(CGG), Glu(GAA), and
Val(GTA) tRNA. Previous methods to remove tRNA involving ethanol-Sepharose matrix
achieved an average of 62% depletion efficiency, with the depletion efficiencies for different
tRNAs varying widely (Cui et al. 2015; Kunda et al. 2000).
The presented method is a significant improvement in efficacy and consistency. Such an
improvement is essential for codon emancipation and reassignment. For example, if 10 codons
are reassigned in a protein 98% of produced product would be correct if only 0.2% of the native
tRNA remained, which is the level of removal reported with Val(GTA) tRNA. However, if 38%
of native tRNA remained and competed for the 10 reassigned codons, less than 1% of produced
protein would be correct. Even at 90% depletion efficiency, the 10% remaining would result in
more than 65% of the product incorrect for a protein with 10 reassigned codons. Thus, high
tRNA removal efficiency reported in this paper is essential for facilitating true codon
emancipation for reassignment. Equally important, the reported tRNA emancipated cell-free
system is capable of producing protein at yields (~300 µg/ml) and costs (~$6 /mg) that are
reasonable for widespread commercial and research applications (Shrestha et al. 2014). For
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example, these results show that the presented method can approximate the near tRNA-free
environment of a customized PURE system (Iwane et al. 2016), but with higher yields and at a 2
to 3 fold magnitude reduction in cost (Ranji et al. 2013; Shrestha et al. 2014). In conclusion,
quantification of tRNA removal is essential to verifying near 100% tRNA removal and such an
optimized cell-free protein synthesis platform holds great promise for widespread use of codon
reassigned systems.

Figure 8-5: Synthetic tRNA production.
a) T7-Hammerhead ribozyme-tRNA DNA construct for making fMet and Val tRNA. Hammerhead
ribozyme cleaves itself exactly at the targeted position, resulting in the correct tRNA sequence. b) TBEUrea gel electrophoresis of the in vitro transcription reactions to produce tRNAs. c) The DNA sequence
used for producing fMet and Val tRNA.

8.3.3

CFPS of Peptides Using Treated Cell Extract and Synthetic tRNA
Previously Cui et al. and others have demonstrated that tRNA can be synthesized using in

vitro transcription of a T7-promoted tRNA platform (Cui et al. 2015). Additionally, Iwane et al.
demonstrated the use of flexizyme to produce functional tRNA, which was used at higher
concentrations in the tRNA depleted PURE system (Iwane et al. 2016). Here, we demonstrate
that synthetic tRNAs are also compatible with the RNase-treated extract reported above for
protein synthesis. To this end, synthetic tRNAs for fMet and Val were produced with a preceding
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hammerhead ribozyme to yield precise tRNA sequences (Figure 8-5a) (Albayrak and Swartz
2013; Fechter et al. 1998). Synthetic tRNA for fMet and Val were added at optimized
concentrations to produce the designer peptide containing the formylmethionine and valine
(Figure 8-6a). The synthetic tRNA produced protein at the same yields as bulk purified tRNA
(Figure 8-6b), demonstrating successful codon emancipation and use of the system with
synthetic tRNA.

Figure 8-6: Protein synthesis with tRNA depleted cell extract and synthetic tRNAs.
a) A peptide was designed to contain fMet as starting sequence for the translation process followed by 40
Val residues, with protein synthesis yield determined using C14-labled Val. b) Cell-free protein synthesis
of the poly-Val peptide using the 30 min RNase A treated extract. The peptide synthesis yields were
normalized based on the control reaction with bulk-purified tRNA (yield of 170 μg/ml). In vitro
transcribed synthetic tRNA was added to the cell-free protein synthesis system at 100 μg/ml fMet and 500
μg/ml Val, while the bulk-purified tRNA was added at 2 mg/ml. The error bars represent one standard
deviation for n=3.

Conclusion
In this study, we developed a robust method to emancipate codons at greater than 99%
efficiencies. This was done by efficiently and affordably degrading native tRNAs of E. coli cell
extracts, which previously had been a key technical challenge. The presented approach resulted
in 2000-fold decreases in native tRNA level compared to untreated extract, while also preserving
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protein synthesis activity of the cell extract. Most importantly, the approach maintains high level
protein production (~300 mg/ml) at low cost (~$6 /mg) for widespread use. We also
demonstrated that the treated extract can be used with synthetic tRNAs for protein synthesis.
Overall, codon emancipation is an essential and typically limiting step in codon-tRNA-amino
acid reassignment and holds great promise in expanding proteomic toolset.
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SUPPLEMENTARY MATERIAL TO CHAPTER 8

Figures

Figure 9-1: Schematic diagram of extract treatment to deplete endogenous tRNA.
Ribonuclease A was attached to superparamagnetic beads covalently. After extensively washing steps to
remove the unattached enzyme, the beads were added to PMSF treated extract. Later the treated extract
was separated and transferred to the new microcentrifuge tube.
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Ladder (60-100 bases)
Roche bulk-purified
tRNA
Untreated extract
Treated extract

Figure 9-2: Gel electrophoresis of purified tRNA from various extracts.
Gel electrophoresis of purified tRNA from untreated extract, treated extract for 15min, and Roche
purified-bulk tRNA. The gels showed that the treatment significantly decreases the tRNA level.
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Figure 9-3: Effect of treatment time on protein synthesis recovery of cell-extract.
Although increasing the treatment time decrease the tRNA residue level, it decreased the protein synthesis
yield. The treatment time should be optimize based on the application and targeted codons.
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Protein Synthesis
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80%
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40%
20%
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SynDNA

IPA 1x

Trizol/IPA
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Figure 9-4: Effect of different syntRNA purification methods on the in vitro transcription.
SynDNA: adding DNA template of tRNA without doing IVT reaction directly to the CFPS, IPA 1x:
purifying IVT product with one-time isopropanol; Ammonium acetate precipitation, Trizol/IPA 1x:
Purifying IVT product using first trizol and then IPA 1x, IPA 2x: Performing IPA two times. All tRNA
and DNA were added to the cell-free protein synthesis reaction at the same concentration.

Figure 9-5: In vitro transcription of T7-tRNA.
a) DNA construct of T7-tRNA and T7-HH Ribozyme-tRNA. b) TBE-Urea Gel electrophoresis of IVT
product of two constructs. c) Performance comparison of two types of SyntRNA in recovery of protein
synthesis. d) Performance comparison of purified-bulk tRNA and T7-HH Ribozyme-tRNA in recovery of
protein synthesis.
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Figure 9-6: Verifying the activity of MjTyrtRNA/RS orthogonal pair using T216Amb sfGFP.
a) CFPS of T216Amb sfGFP in absence and presence of MjTyrtRNATAG. In the case of not adding the
tRNA to incorporate uAA at amber stop codon, no full length sfGFP was detected. By adding the tRNA,
full-length sfGFP was produced. b) Optimizing the concentration of MjTyrtRNATAG and synthetase using
T216Amb sfGFP construct. The concentration of MjTyrRS was between 0.4 to 4 mg/ml, and the
MjTyrtRNATAG was between 100 to 2000 µg/ml.
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Figure 9-7: Effect of deacylated tRNA on protein synthesis.
Adding back purified-bulk tRNA to the CFPS of sfGFP using treated cell-extract at first increased the
protein synthesis, but adding more than 1 mg/ml of deacylated tRNA hindered protein synthesis.
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Figure 9-8: Incorporation of uAAs at CAC sense codon.
The results are similar to that of Figure 5-4 suggesting that uAA incorporation is successful.
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Tables
Table 9-1: List of primers used for q-RT-PCR.

Codon
AntiResidue Codon
(5` to
(5` to 3`) 3`)

Reverse primer (5' to 3')

Forward Primer (5' to 3')

Ala

GGC

GCC

GCT GAC CTC TTG CAT GCC AT

GGG GCT ATA GCT CAG CTG G

Arg

CCG

CGG

CCT GAG ACC TCT GCC TCC GGA

GCG CCC GTA GCT CAG CTG GAT A

Glu

UCC

GAA

CCC CTG TTA CCG CCG TGA AAG G

GTC CCC TTC GTC TAG AGG CCC
AG

Ser

CGA

UCG

GTA GAG TTG CCC CTA CTC CGG T GGA GAG ATG CCG GAG CGG

Val

UAC

GUA

CGC CGA CCC CCT CCT TGT AAG

GGG TGA TTA GCT CAG CTG GGA
GAG C

Table 9-2: DNA sequence of constructs for fMet, Val, and three Mj Tyr tRNA variants.

Residue T7

Hammerhead Ribozyme

tRNA Sequence*

fMet
(AUG)

TAATACGACTC CGCGCTGATGAGTCCGT CGCGGGGTGGAGCAGCCTGGTAGCTCGTC
ACTATAGGGAG GAGGACGAAACGGTACC GGGCTCATAACCCGAAGGTCGTCGGTTCA
A
CGGTACCGTC
AATCCGGCCCCCGCAACC

Val
(GTA)

TAATACGACTC CACCCCTGATGAGTCCG GGGTGATTAGCTCAGCTGGGAGAGCACCT
ACTATAGGGAG TGAGGACGAAACGGTAC CCCTTACAAGGAGGGGGTCGGCGGTTCGA
TCCCGTCATCACCCACC
A
CCGGTACCGTC

Mj
(GCC)

TAATACGACTC CCGGCTGATGAGTCCGT CCGGCGGTAGTTCAGCAGGGCAGAACGGC
ACTATAGGGAG GAGGACGAAACGGTACC GGACTGGCAATCCGCATGGCAGGGGTTCA
A
CGGTACCGTC
AATCCCCTCCGCCGGACCA

Mj
(CAC)

TAATACGACTC CCGGCTGATGAGTCCGT CCGGCGGTAGTTCAGCAGGGCAGAACGGC
ACTATAGGGAG GAGGACGAAACGGTACC GGACTGTGAATCCGCATGGCAGGGGTTCA
A
CGGTACCGTC
AATCCCCTCCGCCGGACCA

Mj
(TAG)

TAATACGACTC CCGGCTGATGAGTCCGT CCGGCGGTAGTTCAGCAGGGCAGAACGGC
ACTATAGGGAG GAGGACGAAACGGTACC GGACTCTAAATCCGCATGGCAGGGGTTCA
A
CGGTACCGTC
AATCCCCTCCGCCGGACCA

*The anticodon is emphasized in red.
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GCA

5.04

Arg

CGU

ACG

64.25

7.37

Asn

AAC

GUU

82.75

1.85

Asp

GAC

GUC

53.95

3.72

Cys

UGC

GCA

61.15

2.46

Gln

CAG

CUG

81.35

1.36

Glu

GAA

UUC

75.35

7.32

Gly

GGC

GCC

42.83

6.76

His

CAC

GUG

70.23

0.99

Ini

AUG

CAU

100

2.99

Met

AUG

CAU

100

1.09

Ile

AUC

GAU

65.94

5.39

Leu

CUG

CAG

76.67

6.94

Lys

AAA

UUU

78.55

2.97

Phe

UUC

GAA

70.92

1.60

Pro

CCG

CGG

71.89

1.38

Ser

UCC

GGA

26.56

1.18

Thr

ACC

GGU

53.6

1.86

Trp

UGG

CCA

100

1.46

Tyr

UAC

GUA

64.77

3.14

Val

GUA

UAC

19.97

5.96

out of total tRNA

Usage(Henaut
Fraction of tRNA

Ala
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24.01

Codon

E. Coli Genome

UGC

(5` to 3`)

Anti-Codon

Codon (5` to 3`)

Residue

Table 9-3: Minimal set codons, and their codon usage and concentration in E. coli.

10 CONCLUSION & FUTURE WORKS

Unnatural amino acids (uAA) are enabling novel and powerful ways to study and
engineer proteins. While uAA are increasingly used academic and industrial research labs,
several challenges remain. This dissertation has presented cell-free protein synthesis (CFPS) as a
promising tool to address three of these challenges in Chapters 2, 4, 6, and 8 (Table 10-1).
Table 10-1: Presented Challenges and Cell-Free Technology as a Solution

Challenges & Needs

Engineering Facilitated by CFPS

Chapter

Rapid Expression and
Screening of uAA-proteins

Reformatting to Microliter Scale; Direct
addition of heterologous machineries and
assay components

Chapters 2, 4

Expression of functional
uAA-GPCR

Alteration of lipid environment via addition
of nanodiscs

Chapter 6

Construction of minimal
codon set

Wholesale removal of native tRNA,
Addition of synthetic tRNA

Chapter 8

However, much of the presented work has explored CFPS-based methods by proof-ofconcept experiments and model proteins with little practical application. Future works could
demonstrate the robustness and general utility of the presented methods by applying them
towards more complex and practical proteins. This section overviews several potential future
experiments for this purpose.
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Future Works to Chapters 2 and 4
Chapters 2 and 4 demonstrated the use of CFPS to rapidly optimize uAA incorporation in
T4-lysozyme. This approach could benefit industrially relevant biocatalysis systems. For
example, aldehydes are commercially important as fragrances and flavoring agents, and are
responsible for many recognizable scents such as lemon, almond, vanilla, and cinnamon.
However, aldehydes are difficult to manufacture in vivo due to their cytotoxic reactivity
(Kunjapur and Prather 2015). A promising alternative is to produce aldehydes by rationally
assembling enzymatic pathways in vitro (You and Zhang 2013). In such in vitro biocatalysis
system, uAA-mediated enzyme immobilization can increase stability and cost-efficiency (Wu et
al. 2015). Therefore, the method presented in Chapter 2 and 4 could be utilized to optimize uAA
incorporation into an industrially relevant aldehyde-synthesizing enzyme. The carboxylic acid
reductase from Nocardia iowensis, which has been explored for an in vitro aldehyde synthesis
(Kunjapur et al. 2016), could be an appropriate candidate biocatalyst.

Future Works to Chapter 6
Chapter 6 presented a CFPS-based workflow to screen functionally active beta 1
adrenergic receptor (β1AR) with uAA incorporation. While promising, the two screened
incorporation sites are few and topographically constrained to have explanatory power. Future
works should expand the survey of incorporation sites throughout β1AR for practical
applications, and also demonstrate the method’s compatibility with other G-protein coupled
receptors (GPCR).
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10.2.1 Expansion of Surveyed Incorporation Sites
The surveyed locations Y210 and F218 are both found in the second extracellular loop,
proximal to the binding site. These structural contexts may contribute to lower binding activities
of the assayed mutants. The evaluation of a wider range of locations, including those distal to the
binding site, could shed more light on the relationship between β1AR binding activity and uAA
location. Two such locations – L53 by the N-terminus and Q320 on transmembrane loop 6 – are
being investigated. Other locations which could be used in analytical studies are as follows:
•

Ligand binding sites D155, S228, N327, and N346 – on transmembrane helices 3, 5, 6,
and 7 respectively – form a binding region which contracts 2-3 Å upon binding (Warne et
al. 2008a). The following residues could be targeted to observe such movements: L137,
A226, I230, L325, V329, F342, and F345.

•

Cytoplasmic surface of Transmembrane Helix 6 moves rigidly outward 5 Å during
activation (Altenbach et al. 2008). Q320, K304 and K307 could be tracked to observe
such behavior.

•

Intracellular Loop 2 is hypothesized to act as a “switch” for GPCR activation(Burstein et
al. 1998). In particular, Y166 is suspected to play a key role by interacting with highly
conserved residues D155, R156 and Y157. Neighboring residue F164 can be tracked to
infer movements of Y166.

10.2.2 Demonstrate the Method’s Utility for Practical Applications
Fluorescent probes could be site-specifically conjugated to uAA to be used in Förster
resonance energy transfer (FRET) studies, where fluorescence measurements are used to infer
the distances between two fluorophores in a single molecule at nanometer scale (Fricke et al.
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2015; Roy et al. 2008; Uphoff et al. 2010). However, up until now, FRET studies have been
constrained to termini or cysteine residues for fluorophore functionalization, severely limiting
their application space (Brustad et al. 2008). In contrast, uAA enables site-specific labeling of
any residue by bioconjugating the uAA with suitable fluorophores via click chemistry (Brustad
et al. 2008; Halder et al. 2015). The successful site-specific fluorophore labeling of β1AR could
then be used to probe ligand-binding and activation dynamics. Such efforts could benefit from a
collaboration with Dr. Mike Heilemann, an expert of single molecule FRET techniques and
colleague of Dr. Frank Bernhard at the University of Frankfurt. Single molecule FRET methods
require approximately 10-20 µg per sample, which can be comfortably met with the presented
system. The dimensions of β1AR fit within the application range of FRET, from 20 Å to~100 Å.
FRET studies should take into account potential interactions between nanodiscs and
fluorophores, which can be hydrophobic.
The works of Chapter 6 could also be applied for Fourier transform infrared (FTIR)
spectroscopy. FTIR techniques have been used previously with uAA p-azidophenylalanine to
study conformational changes in photoreactive model GPCR rhodopsin (Ye et al. 2010).
Conformational shifts were interpreted from changes in the electrostatic environments of the
uAA’s azido group. The presented CFPS-based method contribute significantly to this previously
reported FTIR method, since active GPCR are produced rapidly and less labor-intensively. In
addition, β1AR is ligand-binding rather than photoreactive, and therefore functionally closer to
other therapeutically relevant GPCR. FTIR is potentially more attractive than FRET studies
discussed above, since it would not require conjugation reactions. A preliminary FTIR
experiment would approximately require 200 μg of purified β1AR at 100 μL of deuterium oxide
(D2O). Collaboration with expert in FTIR is needed to complete experiment design.
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10.2.3 Demonstrate the Method’s Compatibility with Other GPCR
GPCR represent the most prominent and successful drug targets. However, only a small
number of GPCR is currently targeted by marketed drugs, while many other GPCR elucidated by
the Human Genome Project remain “orphaned”. Future works should look to apply proof-ofconcept methods from Chapter 6 to GPCR beyond β1AR. An interesting GPCR for further
studies is the endothelin 1 receptor A, which is a prostate cancer drug target implicated in tumor
proliferation, apoptosis inhibition, and metastasis in multiple cancer types (Irani et al. 2014; Nie
et al. 2014; Rosanò et al. 2013). Notably, it has been functionally expressed and characterized in
cell free systems, albeit at lower yields than β1AR, at 100 µg/ml (Proverbio et al. 2013). A better
understanding of the conformational changes of endothelin 1 receptor A from a close subtype,
the endothelin 1 receptor B, could help develop more targeted prostate cancer drugs with fewer
side effects.

10.2.4 Applying Alternative Cell-Free Systems towards Other Applications
Chapter 6 presents several advantageous techniques which could also be explored outside
GPCR expression. For example, Chapter 6 discussed alternative energy systems and reaction
format that could lend themselves well to lyophilization of CFPS systems for improved
portability and storability (Salehi et al. 2016; Smith et al. 2015; Smith et al. 2014a). The
alternative CFPS system could address several challenges to CFPS lyophilization. For example,
lyophilized CFPS still use expensive and unstable reagents such as spermidine, putrescine,
nicotinamide adenine dinucleotide (NAD) and coenzyme A. The alternative energy system uses
polyethylene glycol and acetyl phosphate instead, which are more affordable and stable. Another
challenge is that lyophilized extracts can have lower expression yields depending on storage
temperature and duration. The continuous exchange cell-free (CECF) format increases CFPS
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yields by providing additional cofactors and removing deleterious side products. This would help
lyophilized CFPS systems accommodate low-yielding proteins or a wider range of storage
methods. Lastly, lyophilized CFPS extracts have shown greater variability in their performance
than standard CFPS systems. Additional supplies of cofactors and buffers could decrease such
variability, leading to more reliable performance. The possible synergy between the presented
alternative CFPS system and lyophilization remains unexplored.
The CECF format could also be applied to other difficult-to-produce proteins, such as
cytotoxic therapeutics. For example, onconase, a toxic ribonuclease derived from the oocytes of
the Northern Leopard Frog, is a potential cancer therapeutic (Ardelt et al. 2008; Fiorini et al.
2015; Smolewski et al. 2014). Conventional oocyte culturing and harvest procedures involve
labor-intensive purification or refolding steps. Recently, active and soluble onconase was
successfully expressed in CFPS at 1.8 mg/mL by manually supplementing the reaction with
tRNAs at optimized intervals to counter the ribonuclease activity of nascent onconase products
(Salehi et al. 2015). However, the tRNA were supplemented manually, resulting in increased
labor and possibly suboptimal yields due to reaction dilution. Alternatively, tRNA could be
supplemented via passive diffusion in a CECF format. In this method, tRNA would be provided
continuously rather than in intervals without any additional labor or volume dilution. In such
case, the molecular weight cut-off of the membrane should be adjusted to allow for tRNA
diffusion.

Future Works to Chapter 8
Chapter 8 demonstrated that tRNA-codon-amino acid relationships could be reorganized
into a minimal genomic code system in CFPS reactions, towards multiple sense codon
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emancipation for uAA incorporation. The fundamental importance of this tool is to significantly
expand the available composition of biomaterials. To this end, the presented method should be
further developed from its proof-of-concept stage, consisting of only methionine and valine
tRNA, to a mature prototype that includes tRNA for all natural amino acids as well as multiple
uAA. This would require the purification and optimization of each tRNA for a minimal codon
set. During this development phase, proteins of intermediate complexity could be expressed to
demonstrate progress and promising utility – such as anti-microbial peptides (Kang et al. 2017)
or lasso peptides (Piscotta et al. 2015).

Limitations of Cell-Free Protein Synthesis
This dissertation has highlighted significant strengths of CFPS as a rapid and versatile
protein expression platform. However, CFPS also has disadvantages which makes it ill-suited for
certain applications. Future works should acknowledge these limitations and, if appropriate,
complement CFPS-based and in vivo methods.
•

Difficult scale-up: CFPS systems are still difficult and expensive to scale up compared
to in vivo systems, which can be scaled up for industrial manufacturing using mature cell
culturing technologies. Therefore, currently CFPS is better suited for low-volume
analytical reactions rather than large-scale production. This weakness may be addressed
in the future by on-going productive research on CFPS scale-up and optimization. For
example, a CFPS system at 100 L scale has been reported in literature (Zawada et al.
2011), and is being utilized by commercial ventures.

•

Lack of post-translational modification: Currently, it is difficult to extensively provide
post-translational modifications on proteins produced in bacterial CFPS systems.
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Modifications such as glycosylation, deamidation, and oxidation can have important
effects on biotherapeutics’ function and immunogenicity (Jefferis 2016). This
shortcoming could be remedied by using eukaryote or mammalian cell-free systems
(Thoring et al. 2016; Zemella et al. 2015). Such alternative CFPS systems, however,
suffer from low yields or labor-intensive extract preparations, compared to the E. colibased system.
•

Lack of cellular context: Some applications of uAA require the cellular context of living
organisms which cannot be adequately replicated in a cell-free environment. For
example, uAA have been used in vivo to study the effects of post-translational
modification on physiological processes (Wilkins et al. 2015; Wilkins et al. 2014; Zhang
et al. 2017). Also, uAA can be used in live cells to study xenobiology and the origin of
life (Acevedo‐Rocha and Budisa 2016; Kubyshkin and Budisa 2017).

Conclusion
uAA are a powerful way to study and engineer proteins. The utility of uAA can be
extended and augmented by CFPS, a rapid and versatile protein expression platform. To
demonstrate this, CFPS was used to (1) rapidly screen multiple locations of uAA in T4lysozyme, (2) incorporate uAA into functionally folded G-protein coupled receptor which has
been challenging to express conventionally, and (3) re-engineer tRNA-codon-amino acid
relationships towards multiple uAA incorporation. CFPS’s ability to tolerate cytotoxic elements
and accommodate extensive modifications to its translational environment were integral to these
successes. Future works should further develop these methods by applying them to more
challenging and practical proteins.
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